CA2844388A1 - Process and intermediates for preparing macrolactams - Google Patents
Process and intermediates for preparing macrolactams Download PDFInfo
- Publication number
- CA2844388A1 CA2844388A1 CA2844388A CA2844388A CA2844388A1 CA 2844388 A1 CA2844388 A1 CA 2844388A1 CA 2844388 A CA2844388 A CA 2844388A CA 2844388 A CA2844388 A CA 2844388A CA 2844388 A1 CA2844388 A1 CA 2844388A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- salt
- compounds
- added
- making
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C35/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic
- C07C35/04—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a three or four-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C271/34—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/14—Preparation of carboxylic acid esters from carboxylic acid halides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/013—Esters of alcohols having the esterified hydroxy group bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/12—Acetic acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
- C07K5/126—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
The present invention includes compounds useful as intermediates in the preparation of macrolactams, methods for preparing the intermediates, and methods for preparing macrolactams from the intermediates. One use of the methods and intermediates described herein is in the production of macrolactam compounds able to inhibit HCV NS3 protease activity. HCV NS3 inhibitory compounds have therapeutic and research applications.
Description
TITLE OF THE APPLICATION
PROCESS AND INTERMEDIATES FOR PREPARING MACROLACTAMS
FIELD OF THE INVENTION
The present invention relates to process and intermediates that can be used for preparing macrolactams. One use of the methods and intermediates described herein is the production of macrolactam compounds able to inhibit HCV NS3 protease activity.
inhibitory compounds have therapeutic and research applications.
BACKGROUND OF THE INVENTION
Hepatitis C virus (HCV) infection is a major health problem. HCV infection leads to chronic liver disease, such as cirrhosis and hepatocellular carcinoma, in a substantial number of infected individuals. Several virally-encoded enzymes are putative targets for therapeutic intervention, including a metalloprotease (N52-3), a serine protease (NS3), a helicase (NS3), and an RNA-dependent RNA polymerase (NS5B).
Potential treatments for HCV infection are discussed in different references including Balsano, Mini Rev. Med. Chem. 8(4):307-318, 2008, Winn et al., Current Topics in Medicinal Chemistry 8:533-562, 2008, Sheldon et al., Expert Opin. Investig.
Drugs 16(8):1171-1181, 2007, and De Francesco et al., Antiviral Research 58:1-16, 2003.
Examples of publications describing macrolactam compounds able to inhibit HCV protease activity include McCauley etal., W02011014487; Harper et al., W02010011566;
Liverton et al., W02009134624; McCauley etal., W02009108507; Liverton et al., W02009010804; Liverton et al.,W02008057209; Liverton etal., W02008051477;
Liverton et al.,W02008051514; Liverton et al., W02008057208; Crescenzi et al., W02007148135; Di Francesco etal., W02007131966; Holloway etal., W02007015855; Holloway et al.,W02007015787; Holloway etal., W02007016441; Holloway etal., W02006119061;
Liverton et al., .1 Am. Chem. Soc., 130:4607-4609, 2008; and Liverton et al., Antimicrobial Agents and Chemotherapy 54:305-311, 2010.
SUMMARY OF THE INVENTION
The present invention includes compounds useful as intermediates in the preparation of macrolactams, methods for preparing the intermediates, and methods for preparing macrolactams. One use of the methods and intermediates described herein is the production of macrolactam compounds able to inhibit HCV NS3 protease activity.
inhibitory compounds have therapeutic and research applications.
An example of a HCV inhibitory compound that may be produced using the procedures and intermediates described herein is Compound A, or a pharmaceutically salt thereof:
al 0, q 0 (R)-= N ,S __ (R) .< 1.1 (R) N
.00 (s), OH, Compound A
A first aspect is directed to method of making Compound A comprising the step of coupling is OMe N
0: N
CH
0\ /0 , H N CO2H
'0 N H2N..........õ,:.----...N....S......v ' ,:s",< H
Y
A or salt thereof, to 1 or salt thereof, to form Compound A or salt thereof, wherein the coupling comprises the use of a coupling reagent and pyridine or a pyridine derivative.
Another aspect of the invention is directed to a compound having the structure of Formula I or a salt thereof:
R40(0)c Zy2 Me0 No WI --) N Ri (Formula I), wherein R1 is a leaving group, or )rcõ.= <AO Ny C(0)R3 y (Structure I), provided that if R1 is a leaving group, then R2 is H; and if R1 is Structure I, then R2 is H and R3 is OH, or R2 and R3 are joined together as a covalent bond;
R4 either C1_6 alkyl or aryl; and R5 is either a C1-8 alkyl or C343 cycloalkyl.
Additional aspects of the present invention are directed to a method of making a compound of Formula I.
Another aspect of the present invention is directed to a method of making Compound 18 comprising the steps of:
Me02C
1)1F1 Me02C
Coupling Me0 NIO4 Me0 N 0 N Cl=
Lactamization CO2Me CO2Me 0Hy N
drogenation _________________________________________________________ =
Me0 0.N 0 --\of Me0 Another aspect of the present invention is directed to a method of making Compound 18 comprising the steps of:
PROCESS AND INTERMEDIATES FOR PREPARING MACROLACTAMS
FIELD OF THE INVENTION
The present invention relates to process and intermediates that can be used for preparing macrolactams. One use of the methods and intermediates described herein is the production of macrolactam compounds able to inhibit HCV NS3 protease activity.
inhibitory compounds have therapeutic and research applications.
BACKGROUND OF THE INVENTION
Hepatitis C virus (HCV) infection is a major health problem. HCV infection leads to chronic liver disease, such as cirrhosis and hepatocellular carcinoma, in a substantial number of infected individuals. Several virally-encoded enzymes are putative targets for therapeutic intervention, including a metalloprotease (N52-3), a serine protease (NS3), a helicase (NS3), and an RNA-dependent RNA polymerase (NS5B).
Potential treatments for HCV infection are discussed in different references including Balsano, Mini Rev. Med. Chem. 8(4):307-318, 2008, Winn et al., Current Topics in Medicinal Chemistry 8:533-562, 2008, Sheldon et al., Expert Opin. Investig.
Drugs 16(8):1171-1181, 2007, and De Francesco et al., Antiviral Research 58:1-16, 2003.
Examples of publications describing macrolactam compounds able to inhibit HCV protease activity include McCauley etal., W02011014487; Harper et al., W02010011566;
Liverton et al., W02009134624; McCauley etal., W02009108507; Liverton et al., W02009010804; Liverton et al.,W02008057209; Liverton etal., W02008051477;
Liverton et al.,W02008051514; Liverton et al., W02008057208; Crescenzi et al., W02007148135; Di Francesco etal., W02007131966; Holloway etal., W02007015855; Holloway et al.,W02007015787; Holloway etal., W02007016441; Holloway etal., W02006119061;
Liverton et al., .1 Am. Chem. Soc., 130:4607-4609, 2008; and Liverton et al., Antimicrobial Agents and Chemotherapy 54:305-311, 2010.
SUMMARY OF THE INVENTION
The present invention includes compounds useful as intermediates in the preparation of macrolactams, methods for preparing the intermediates, and methods for preparing macrolactams. One use of the methods and intermediates described herein is the production of macrolactam compounds able to inhibit HCV NS3 protease activity.
inhibitory compounds have therapeutic and research applications.
An example of a HCV inhibitory compound that may be produced using the procedures and intermediates described herein is Compound A, or a pharmaceutically salt thereof:
al 0, q 0 (R)-= N ,S __ (R) .< 1.1 (R) N
.00 (s), OH, Compound A
A first aspect is directed to method of making Compound A comprising the step of coupling is OMe N
0: N
CH
0\ /0 , H N CO2H
'0 N H2N..........õ,:.----...N....S......v ' ,:s",< H
Y
A or salt thereof, to 1 or salt thereof, to form Compound A or salt thereof, wherein the coupling comprises the use of a coupling reagent and pyridine or a pyridine derivative.
Another aspect of the invention is directed to a compound having the structure of Formula I or a salt thereof:
R40(0)c Zy2 Me0 No WI --) N Ri (Formula I), wherein R1 is a leaving group, or )rcõ.= <AO Ny C(0)R3 y (Structure I), provided that if R1 is a leaving group, then R2 is H; and if R1 is Structure I, then R2 is H and R3 is OH, or R2 and R3 are joined together as a covalent bond;
R4 either C1_6 alkyl or aryl; and R5 is either a C1-8 alkyl or C343 cycloalkyl.
Additional aspects of the present invention are directed to a method of making a compound of Formula I.
Another aspect of the present invention is directed to a method of making Compound 18 comprising the steps of:
Me02C
1)1F1 Me02C
Coupling Me0 NIO4 Me0 N 0 N Cl=
Lactamization CO2Me CO2Me 0Hy N
drogenation _________________________________________________________ =
Me0 0.N 0 --\of Me0 Another aspect of the present invention is directed to a method of making Compound 18 comprising the steps of:
Me02C
b1H Me02C
Coupling Me0 a N1:0 Me0 N HN CO2H
N
Hydrogenation aC_N_ Me02C
blF1 HN CO2H Lactamization oi _________________________________________________________ Me0 N 0 Me0 N
Additional aspects of the present include different forms of Compound A, Compound 14 and Compound 19.
5 Other embodiments, aspects and features of the present invention are either further described herein or will be apparent from the ensuing description, examples and appended claims.
BRIEF DESCRIPTION OF THE DRAWINGS
10 Figure 1 illustrates an X-ray diffraction pattern of Compound 19 hydrate 1.
Figure 2 illustrates a solid state C-13 CPMAS NMR for Compound 19 hydrate 1.
Figure 3 illustrates an X-ray diffraction pattern for a MeCN solvate of a Compound 14 methylsulfonic acid salt.
The methods and intermediates described herein can be used to synthesize macrolactams such as Compound A and compounds varying from Compound A by one or more functional group.
Functional groups that can be modified include a different alkyl in place of the t-butyl group, and alteration of the cyclopropylsulfonyl functional group (e.g., with an ethyl group replacing the ethylene and/or a methylcyclopropyl group replacing the cyclopropyl group).
Different intermediates and synthesis protocols are illustrated herein where Compound A was ultimately obtained. However, it is understood that based on the guidance provided herein other macrolactams can be produced using appropriate intermediates and by adding or modifying different functional groups. Examples of different macrolactams having different functional groups are provided in McCauley et aL, W02011014487;
Harper et al., W02010011566; Liverton et al., W02009134624; McCauley et al., W02009108507;
Liverton et al., W02009010804; Liverton et al., W02008057209; Liverton et al., W02008051477; Liverton et aL, W02008051514; Liverton et al., W02008057208; Crescenzi et aL, W02007148135; Di Francesco et al., W02007131966; Holloway et at, W02007015855; Holloway et aL, W02007015787; Holloway et al., W02007016441; Holloway et aL, W02006119061;
Liverton et al., J. Am. Chem. Soc., 130:4607-4609, 2008; and Liverton et aL, Antimicrobial Agents and Chemotherapy 54:305-311, 2010.
Harper et al., W02010011566 describes an alternative method for making Compound A. Harper et al., W02010011566 et al., also includes data illustrating the ability of Compound A to inhibit HCV replicon activity and NS3/4A.
Macrolactam compounds able to inhibit HCV activity have different uses including inhibiting HCV activity in vivo, inhibiting HCV activity in vitro, and inhibiting HCV
NS3 enzymatic activity. In vivo inhibition of HCV activity can be used for therapeutic applications. Inhibiting HCV activity in vitro has different applications including being used to obtain HCV resistant mutants, further characterizing the ability of a functional group to inhibit HCV replicon or enzymatic activity, and studying HCV replication or protease activity.
Macrocyclic Acid Scheme A illustrates an overall scheme that can used to produce a macrolactam.
Different aspects and embodiments of Scheme A are directed to each of the different steps, alone or in any combination with up stream or downstream steps.
b1H Me02C
Coupling Me0 a N1:0 Me0 N HN CO2H
N
Hydrogenation aC_N_ Me02C
blF1 HN CO2H Lactamization oi _________________________________________________________ Me0 N 0 Me0 N
Additional aspects of the present include different forms of Compound A, Compound 14 and Compound 19.
5 Other embodiments, aspects and features of the present invention are either further described herein or will be apparent from the ensuing description, examples and appended claims.
BRIEF DESCRIPTION OF THE DRAWINGS
10 Figure 1 illustrates an X-ray diffraction pattern of Compound 19 hydrate 1.
Figure 2 illustrates a solid state C-13 CPMAS NMR for Compound 19 hydrate 1.
Figure 3 illustrates an X-ray diffraction pattern for a MeCN solvate of a Compound 14 methylsulfonic acid salt.
The methods and intermediates described herein can be used to synthesize macrolactams such as Compound A and compounds varying from Compound A by one or more functional group.
Functional groups that can be modified include a different alkyl in place of the t-butyl group, and alteration of the cyclopropylsulfonyl functional group (e.g., with an ethyl group replacing the ethylene and/or a methylcyclopropyl group replacing the cyclopropyl group).
Different intermediates and synthesis protocols are illustrated herein where Compound A was ultimately obtained. However, it is understood that based on the guidance provided herein other macrolactams can be produced using appropriate intermediates and by adding or modifying different functional groups. Examples of different macrolactams having different functional groups are provided in McCauley et aL, W02011014487;
Harper et al., W02010011566; Liverton et al., W02009134624; McCauley et al., W02009108507;
Liverton et al., W02009010804; Liverton et al., W02008057209; Liverton et al., W02008051477; Liverton et aL, W02008051514; Liverton et al., W02008057208; Crescenzi et aL, W02007148135; Di Francesco et al., W02007131966; Holloway et at, W02007015855; Holloway et aL, W02007015787; Holloway et al., W02007016441; Holloway et aL, W02006119061;
Liverton et al., J. Am. Chem. Soc., 130:4607-4609, 2008; and Liverton et aL, Antimicrobial Agents and Chemotherapy 54:305-311, 2010.
Harper et al., W02010011566 describes an alternative method for making Compound A. Harper et al., W02010011566 et al., also includes data illustrating the ability of Compound A to inhibit HCV replicon activity and NS3/4A.
Macrolactam compounds able to inhibit HCV activity have different uses including inhibiting HCV activity in vivo, inhibiting HCV activity in vitro, and inhibiting HCV
NS3 enzymatic activity. In vivo inhibition of HCV activity can be used for therapeutic applications. Inhibiting HCV activity in vitro has different applications including being used to obtain HCV resistant mutants, further characterizing the ability of a functional group to inhibit HCV replicon or enzymatic activity, and studying HCV replication or protease activity.
Macrocyclic Acid Scheme A illustrates an overall scheme that can used to produce a macrolactam.
Different aspects and embodiments of Scheme A are directed to each of the different steps, alone or in any combination with up stream or downstream steps.
Scheme A
R,o(o)c R40(0)c PG
1)1H
i OMe i.NAR bl S 2. Deprotect IW- displacement,i NMe0 Nij.) ___ Ri,y Ha c.-.
CO2Me Me0 am N A io R5 N N Ri HOOCNH
Ri PG µP.1 N R1 12A 3. Coupling C(0)0R4 n'I-5_NH 5. Hydrogenation C(0)0R4 (NO
,, _________________________________________ / -5,__ 4. Lactamization R40(0)C
Me ah N, 0 R5 \
0 -.----- Me0 N 0 R5 NH 1)µ1H
Q al o..--- R5 IWi N 0 18A 1 -"\e4' Me0 0 NO 0 0 17A N \
R,o(o)c R40(0)c PG
1)1H
i OMe i.NAR bl S 2. Deprotect IW- displacement,i NMe0 Nij.) ___ Ri,y Ha c.-.
CO2Me Me0 am N A io R5 N N Ri HOOCNH
Ri PG µP.1 N R1 12A 3. Coupling C(0)0R4 n'I-5_NH 5. Hydrogenation C(0)0R4 (NO
,, _________________________________________ / -5,__ 4. Lactamization R40(0)C
Me ah N, 0 R5 \
0 -.----- Me0 N 0 R5 NH 1)µ1H
Q al o..--- R5 IWi N 0 18A 1 -"\e4' Me0 0 NO 0 0 17A N \
6. Hydrolysis I
5B. Lactamization HO2C 0 R if 4B.
Hydrogenation R40(0)C R5 -r blF1 N 6 0,,. HN-I'CO2H
Me0 al 1 T.....,..",...õ.õ..) ,fA0 lir N Me0 coi N
19A itliFi N
The compounds illustrated in Scheme A are in the neutral form. It should be understood that different embodiments described throughout the application include appropriate acid or base forms of the different compounds.
"PG" refers to a protecting group. In different embodiments described throughout the application where a protecting group is employed: PG is an acid-labile carbomate; PG is BOC, Fmoc, 9-Anthrylmethyl, Msz, Moz, or Cbz; or PG is Boc.
each R1 is a leaving group as described for Formula below, including different embodiments.
R4 is as described for Formula I, including different embodiments as provided below.
R5 is as described for Structure I, including different embodiments as provided below.
A preferred overall scheme is illustrated in scheme B. Further aspects and embodiments of Scheme B are directed to each of the different steps, alone or in any combination with up stream or downstream steps.
Scheme B
Me02C
OM . S OeM o2C .B c b1H
e =1)µ1 2. Deprotect 0 displacement R
N =Mn e0 a N:co _________________________________________________ _, CI)yl HO, 0. --.........--CO2Me Me0 Ai NIO
5B. Lactamization HO2C 0 R if 4B.
Hydrogenation R40(0)C R5 -r blF1 N 6 0,,. HN-I'CO2H
Me0 al 1 T.....,..",...õ.õ..) ,fA0 lir N Me0 coi N
19A itliFi N
The compounds illustrated in Scheme A are in the neutral form. It should be understood that different embodiments described throughout the application include appropriate acid or base forms of the different compounds.
"PG" refers to a protecting group. In different embodiments described throughout the application where a protecting group is employed: PG is an acid-labile carbomate; PG is BOC, Fmoc, 9-Anthrylmethyl, Msz, Moz, or Cbz; or PG is Boc.
each R1 is a leaving group as described for Formula below, including different embodiments.
R4 is as described for Formula I, including different embodiments as provided below.
R5 is as described for Structure I, including different embodiments as provided below.
A preferred overall scheme is illustrated in scheme B. Further aspects and embodiments of Scheme B are directed to each of the different steps, alone or in any combination with up stream or downstream steps.
Scheme B
Me02C
OM . S OeM o2C .B c b1H
e =1)µ1 2. Deprotect 0 displacement R
N =Mn e0 a N:co _________________________________________________ _, CI)yl HO, 0. --.........--CO2Me Me0 Ai NIO
Cl N N CI
=Boc IPI N CI
12 3. Coupling CO2Me 1/\10 5. Hydrogenation CO2Me N 4. Lactamization NH =CV/ NH Me02C
Me0 a N,..._____\.Aci' ____________________________ Me0 a Nx\__Ho.._.___ 1,iFI
µFl HNCO2H N :
N _ Me0 410 N 6 0 0 6. Hydrolysis I
5B. Lactamization HO2C 0 t< i, 4B.
Hydrogenation OrlY
HNY0 Me I)AH
Oh.
Me0 16 Nx.,7...õ....,......_...)>6 HNCO2H
IV N Me0 An aspect of the invention is directed to a compound Formula I or a salt thereof:
R40(0)C .
?N)1R2 Me0 0 NO
.7., = (Formula I), wherein R1 is a leaving group, or õ.<4.0 N C(0)R3 y y 5 (Structure I), provided that if R1 is a leaving group, then R2 is H; and if R1 is Structure I, then R2 is H and R3 is OH, or R2 and R3 are joined together as a covalent bond;
R4 either C1.6 alkyl or aryl; and R5 is either a C1-8 alkyl or C3-8 cycloalkyl.
In a first embodiment the R1 leaving group is a halogen, mesylate, tosylate or CF3S03.
In a second embodiment the R1 leaving group is a halogen.
In a third embodiment the R1 leaving group is a Cl.
In a fourth embodiment R1 is Structure I.
In a fifth embodiment R4 is C16 alkyl and R1 is as provided in the Formula I
or embodiments 1-4.
In a sixth embodiment R4 is methyl and Ri is as provided in the Formula I or embodiments 1-4.
In a seventh embodiment R5 is t-butyl and the other variables are as provided in the Formula I or embodiments 1-6.
In an eighth embodiment R5 is cyclohexyl and the other variables are as provided in the Formula I or embodiments 1-6.
In a ninth embodiment the compound is either:
Me02C
Me02C
1)µIH
Me0 N
Me0 NO = 0 0 N
N CI (Compound 14), (Compound 16), CO2Me Me0 N 0 ___ N
(Compound 17); or a salt thereof In a tenth embodiment, Compound 14 is a methylsulfonic acid salt and/or a MeCN solvate.
A first aspect is directed to a method of making Compound 16A
=Boc IPI N CI
12 3. Coupling CO2Me 1/\10 5. Hydrogenation CO2Me N 4. Lactamization NH =CV/ NH Me02C
Me0 a N,..._____\.Aci' ____________________________ Me0 a Nx\__Ho.._.___ 1,iFI
µFl HNCO2H N :
N _ Me0 410 N 6 0 0 6. Hydrolysis I
5B. Lactamization HO2C 0 t< i, 4B.
Hydrogenation OrlY
HNY0 Me I)AH
Oh.
Me0 16 Nx.,7...õ....,......_...)>6 HNCO2H
IV N Me0 An aspect of the invention is directed to a compound Formula I or a salt thereof:
R40(0)C .
?N)1R2 Me0 0 NO
.7., = (Formula I), wherein R1 is a leaving group, or õ.<4.0 N C(0)R3 y y 5 (Structure I), provided that if R1 is a leaving group, then R2 is H; and if R1 is Structure I, then R2 is H and R3 is OH, or R2 and R3 are joined together as a covalent bond;
R4 either C1.6 alkyl or aryl; and R5 is either a C1-8 alkyl or C3-8 cycloalkyl.
In a first embodiment the R1 leaving group is a halogen, mesylate, tosylate or CF3S03.
In a second embodiment the R1 leaving group is a halogen.
In a third embodiment the R1 leaving group is a Cl.
In a fourth embodiment R1 is Structure I.
In a fifth embodiment R4 is C16 alkyl and R1 is as provided in the Formula I
or embodiments 1-4.
In a sixth embodiment R4 is methyl and Ri is as provided in the Formula I or embodiments 1-4.
In a seventh embodiment R5 is t-butyl and the other variables are as provided in the Formula I or embodiments 1-6.
In an eighth embodiment R5 is cyclohexyl and the other variables are as provided in the Formula I or embodiments 1-6.
In a ninth embodiment the compound is either:
Me02C
Me02C
1)µIH
Me0 N
Me0 NO = 0 0 N
N CI (Compound 14), (Compound 16), CO2Me Me0 N 0 ___ N
(Compound 17); or a salt thereof In a tenth embodiment, Compound 14 is a methylsulfonic acid salt and/or a MeCN solvate.
A first aspect is directed to a method of making Compound 16A
OMe R40(0)C
1)\1H
N,COOH R5 R N
rr Y HN.v.0O2H
NC(0)0R4 Me0 wherein Compound 14A, 15A, and 16A may be provided as a salt. Reference to different compounds in a reaction possibly (e.g., may be) being provided as a salt indicates that any one compound, any combination of compounds, or all of the compounds may be provided as a salt;
R1 is a leaving group as described above in the aspects and embodiments directed to a compound of Formula I or a salt thereof; and R4 and R5 are as described above in the aspects and embodiments directed to a compound of Formula I or a salt thereof In a further embodiment Compound 16 is made by a method comprising the step of:
OMe Me02C
H 1)\1 CIN N,C0 y 2 =
Me , 1-1 HN CO2H
b Y
N)--0O2Me = N
wherein Compounds 14, 15, and 16 may be provided as a salt.
In different embodiments concerning the compounds used in the reaction, 15 Compound 14 is a methylsulfonic acid salt, Compound 14 is a MeCN solvate of a methylsulfonic acid salt, and/or Compound 15 is a TBA salt or DBA salt.
In embodiments concerning the reaction conditions for making 16A or Compound 16, Sonogashira cross coupling using a suitable catalyst is carried out.
Suitable catalysts include a combination of copper halide with palladium salts. In different embodiments, the catalyst is Copper(I) iodide, Copper(I) bromide, Copper(I) chloride, or Copper (I) cyanide. The use of a combination of Copper(I) iodide and bis(triphenylphosphine)palladium(II) dichloride in the presence of an amine base is preferred.
Suitable solvents include alcohols, THF, or MeCN. Examples of alcohols that can be used include methanol, ethanol, propanol and isopropanol.
Preferred amine bases are triethyl amine, tributyl amine, Hunig's base, t-butylamine, and diisopropylamine.
A preferred general temperature range is ¨20-80 C, more preferable the temperature is about 30-50 C, or further specified to 35 C.
In a further embodiment, Compound 17 or 17A is formed by lactamization of compound 16 or 16A. Lacatamization can be carried out using techniques described herein.
A second aspect is directed to a method of making Compound 17 comprising:
Me02C
Me02C
Coupling b1H
Lactamization WO 40 Na0 HN CO2H
Me0 N b N CI
CO2Me H
Me0 N 0 __ wherein compound 14, 15, 16, and 17 may be provided as a salt, and Compound 16 is not 15 isolated prior to lactamization.
Different embodiments concerning coupling are as provided above in the embodiments concerning making Compound 16.
Intermediate Compound 16 does not need to be isolated, and can be used directly as a crude stream after aqueous workup. It is better to control the water content in the reaction mixture to minimize the formation of by-products and to improve the yield. The KF spec is preferably KF <2000 ppm, preferably <500 ppm. In different embodiments the reaction is carried out at -10 to 50 C, preferably at 0 C; and Compound 16 is added slowly, preferably over 10 hours.
Suitable solvents include DMAc, DMF, NMP, methylenechloride, IPAc, Et0Ac, and THF. DMAc is preferred. Various lactamization coupling reagents can be used, such as HATU, EDC, EDC-HOBT, EDC-pyridine, EDC-HOAT, EDC-HOPO, CIP, EDC-HOSu, EDC-PFP, T3P, and HATU/EDC variants The use HATU is preferred.
A third aspect is a directed to a method of making Compound 18 or salt thereof comprising the step of hydrogenation of Compound 17 or salt thereof. Suitable conditions include the use of a palladium catalyst and a solvent. Examples of solvents include THF, Me-THF, methyl cyclopentyl ether, Et0Ac, IPAc, Me0H, Et0H, propanol, isopropanol, DMAc.
THF is a preferred solvent. A general temperature range is temperature from 0 ¨40 C, preferably 15 ¨25 C.
A fourth aspect is directed to a method of making Compound 19 or salt thereof comprising the step of hydrolyzing Compound 18 or a salt thereof. Suitable conditions include the use of bases such as NaOH, LiOH and KOH in aqueous solvents such as MeTHF, THF, Me0H, Et0H, IPA and n-propyl alcohol. A general temperature range is 0-80 C, preferably 40-50 C. In an embodiment, Compound 19 is provided as a hydrate.
A fifth aspect is directed to a method of making Compound 18 comprising:
Me02C
Me02C
Coupling .1)1H
Me0õcjN,,0 HNCO2H
I
Nj CI
HO2C,NH Me0 Hydrogenation CO2Me Me02C
b1H
Me0 NO
HN-ThO2H Lactamization NH
Me0 N 0 zo N
µI1F N
wherein compounds 14, 15, 16, 21, and 18 may be provided as salts, and Compound 16 and 21 are not isolated.
1)\1H
N,COOH R5 R N
rr Y HN.v.0O2H
NC(0)0R4 Me0 wherein Compound 14A, 15A, and 16A may be provided as a salt. Reference to different compounds in a reaction possibly (e.g., may be) being provided as a salt indicates that any one compound, any combination of compounds, or all of the compounds may be provided as a salt;
R1 is a leaving group as described above in the aspects and embodiments directed to a compound of Formula I or a salt thereof; and R4 and R5 are as described above in the aspects and embodiments directed to a compound of Formula I or a salt thereof In a further embodiment Compound 16 is made by a method comprising the step of:
OMe Me02C
H 1)\1 CIN N,C0 y 2 =
Me , 1-1 HN CO2H
b Y
N)--0O2Me = N
wherein Compounds 14, 15, and 16 may be provided as a salt.
In different embodiments concerning the compounds used in the reaction, 15 Compound 14 is a methylsulfonic acid salt, Compound 14 is a MeCN solvate of a methylsulfonic acid salt, and/or Compound 15 is a TBA salt or DBA salt.
In embodiments concerning the reaction conditions for making 16A or Compound 16, Sonogashira cross coupling using a suitable catalyst is carried out.
Suitable catalysts include a combination of copper halide with palladium salts. In different embodiments, the catalyst is Copper(I) iodide, Copper(I) bromide, Copper(I) chloride, or Copper (I) cyanide. The use of a combination of Copper(I) iodide and bis(triphenylphosphine)palladium(II) dichloride in the presence of an amine base is preferred.
Suitable solvents include alcohols, THF, or MeCN. Examples of alcohols that can be used include methanol, ethanol, propanol and isopropanol.
Preferred amine bases are triethyl amine, tributyl amine, Hunig's base, t-butylamine, and diisopropylamine.
A preferred general temperature range is ¨20-80 C, more preferable the temperature is about 30-50 C, or further specified to 35 C.
In a further embodiment, Compound 17 or 17A is formed by lactamization of compound 16 or 16A. Lacatamization can be carried out using techniques described herein.
A second aspect is directed to a method of making Compound 17 comprising:
Me02C
Me02C
Coupling b1H
Lactamization WO 40 Na0 HN CO2H
Me0 N b N CI
CO2Me H
Me0 N 0 __ wherein compound 14, 15, 16, and 17 may be provided as a salt, and Compound 16 is not 15 isolated prior to lactamization.
Different embodiments concerning coupling are as provided above in the embodiments concerning making Compound 16.
Intermediate Compound 16 does not need to be isolated, and can be used directly as a crude stream after aqueous workup. It is better to control the water content in the reaction mixture to minimize the formation of by-products and to improve the yield. The KF spec is preferably KF <2000 ppm, preferably <500 ppm. In different embodiments the reaction is carried out at -10 to 50 C, preferably at 0 C; and Compound 16 is added slowly, preferably over 10 hours.
Suitable solvents include DMAc, DMF, NMP, methylenechloride, IPAc, Et0Ac, and THF. DMAc is preferred. Various lactamization coupling reagents can be used, such as HATU, EDC, EDC-HOBT, EDC-pyridine, EDC-HOAT, EDC-HOPO, CIP, EDC-HOSu, EDC-PFP, T3P, and HATU/EDC variants The use HATU is preferred.
A third aspect is a directed to a method of making Compound 18 or salt thereof comprising the step of hydrogenation of Compound 17 or salt thereof. Suitable conditions include the use of a palladium catalyst and a solvent. Examples of solvents include THF, Me-THF, methyl cyclopentyl ether, Et0Ac, IPAc, Me0H, Et0H, propanol, isopropanol, DMAc.
THF is a preferred solvent. A general temperature range is temperature from 0 ¨40 C, preferably 15 ¨25 C.
A fourth aspect is directed to a method of making Compound 19 or salt thereof comprising the step of hydrolyzing Compound 18 or a salt thereof. Suitable conditions include the use of bases such as NaOH, LiOH and KOH in aqueous solvents such as MeTHF, THF, Me0H, Et0H, IPA and n-propyl alcohol. A general temperature range is 0-80 C, preferably 40-50 C. In an embodiment, Compound 19 is provided as a hydrate.
A fifth aspect is directed to a method of making Compound 18 comprising:
Me02C
Me02C
Coupling .1)1H
Me0õcjN,,0 HNCO2H
I
Nj CI
HO2C,NH Me0 Hydrogenation CO2Me Me02C
b1H
Me0 NO
HN-ThO2H Lactamization NH
Me0 N 0 zo N
µI1F N
wherein compounds 14, 15, 16, 21, and 18 may be provided as salts, and Compound 16 and 21 are not isolated.
Examples of suitable hydrogenation conditions are as described for hydrogenating Compound 17 above.
Examples of suitable lactamization conditions are as described for lactamization of Compound 16 above.
A sixth aspect is direct to a method of making Compound 14 comprising the steps:
Me02C
Me02C .PG
)¨NH
OMe 1. SNAR 1)\1 2.
Deprotection displacement, Me() NO
CI)IN HO,0CO2Me Me0 NO
-CI
N CI
Examples of suitable lactamization conditions are as described for lactamization of Compound 16 above.
A sixth aspect is direct to a method of making Compound 14 comprising the steps:
Me02C
Me02C .PG
)¨NH
OMe 1. SNAR 1)\1 2.
Deprotection displacement, Me() NO
CI)IN HO,0CO2Me Me0 NO
-CI
N CI
wherein compound 11, 12, 13 and 14 may be provided as a salt, and Compound 13 is not isolated.
The reaction can be carried out by SNAR replacement of Compound 11 with Compound 12 in the presence of a base. Compound 11 is described by Sarges et al., J. Med.
Chem. 33:2240-2254, 1990. A general temperature for the reaction is 20-100 C, with a preferred temperature being 40-45 C. A wide range of solvents can be using including aprotic polar solvents, DMF, DMAc, NMP, DMSO, and DMPU. A preferred solvent is DMAc.
Different bases can be used including Cs2CO3, DBU, K2CO3, K3PO4, and KOtBu. A
preferred base is DBU. An advantage of the reaction was high regioselectivity and no detected isomerization of the hydroxyproline.
Deprotection can be carried out with various acids including pTSA, PhS03H, MeS03H, HC1, H2SO4, HBr, Ac0H-HC1 in a wide range solvents including IPAc, Et0Ac, MeCN, and DMAc. The use of methansulfonic acid in MeCN is preferred allowing direct isolation of Compound 14 as a MeCN solvate MeS03I1 salt from the reaction mixture. A general temperature for the reaction is 0-80 C, with a preferred temperature being ¨40 C.
Examples of combinations of upstream and downstream steps include methods comprising: Aspects 1, 3, 4 and 6; Aspects 2, 3, 4 and 6; Aspects 4, 5 and 6;
and subsets within these combinations. Methods directed to subsets comprising adjacent steps, or a series of adjacent steps. For examples, subsets within the combination of Aspects 1, 3, 4 and 6, include a method comprising 1 and 3; 1, 3, and 4; 1, 3, 4, and 6; 6 and 1; 3 and 4; and so forth.
Compound A
Another aspect is directed to method of making Compound A comprising the step of coupling:
ioi OMe N
f)yN
/C)C-= 02H Fi2NN.S.,,,v 0 \tf iFµL N S:" H
\
Compound 20 Compound 19 or salt thereof, to or salt thereof, to form Compound A or salt thereof, wherein the coupling comprises the use of a coupling reagent and pyridine or a pyridine derivative.
Preferably, no detectable HOBt is present. The reaction can be carried out using a coupling reagent, an aprotic organic solvent and pyridine or a pyridine derivative. A general temperature is -10 C to 50 C (preferably 0 to 20 C). Examples of coupling reagents include dicyclohexylcarbodiimide (DCC), N,N'-diisopropylcarbodiimide (DIC), and 1-ethy1-3-(3-dimethylaminopropyl) carbodiimide (EDC), and HATU. Examples of aprotic organic solvents include acetonitrile, THF, THF-DMAc, THF-DMF, THF-NMP, and toluene. In an embodiment, THF-DMAc or THF is used.
In different embodiments EDC is used; EDC is used along pyridine and acetonitrile; EDC is used along with at least 10 equivalents of pyridine and acetonitrile; and EDC
is used along with pyridine and THF-DMAc.
In an embodiment, directed to using EDC with THF-DMAc, Compound 19 hydrate is azeotropically dried in THF, and combined with Compound 20 and DMAc, followed by addition of pyridine or a pyridine derivative and EDC. A preferred temperature range is from about 0 C to 20 C, preferably at 0-5 C for 1 hour followed by 15-20 C for additional 1-2 hours. The use of reaction conditions employing THF-DMAc or THF in conjunction with EDC
facilitates control of the reaction profile and suppression of the formation of by-products, for example, by reducing the over reaction of coupling agent. Alternative procedures could result in significant over reaction of coupling agent with compound A in the absence of quenching.
In an embodiment, Compound 20 used in this aspect, including any of the embodiments, is pTSA salt.
Preferred pyridine derivatives have electron donating or neutral groups at the and 4 position. Examples of general structures covering pyridine and derivatives include:
N
wherein R5 is either hydrogen, aryl, halogen, C1-6 alkyl, 0-C1-6 alkyl or C3-cycloalkyl. Preferred reagents are pyridine, 4-phenylpyridine, 4-alkylpyridine, methylpyridine, 3- or 4- mono or dialkylpyridine, wherein the alkyl group can be a C1-6 alkyl.
Compounds The term "alkyl" refers to a monovalent straight or branched chain, saturated aliphatic hydrocarbon radical having a number of carbon atoms in the specified range. Thus, for example, "C1-6 alkyl" refers to any of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and t-butyl, n- and iso- propyl, ethyl, and methyl. As another example, "Ci 4 alkyl"
refers to n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl, and methyl.
The term "cycloalkyl" refers to any monocyclic ring of an alkane having a number of carbon atoms in the specified range. Thus, for example, "C3_8 cycloalkyl" (or "C3-C8 cycloalkyl") refers to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
The term "halogen" (or "halo") refers to fluorine, chlorine, bromine and iodine (alternatively referred to as fluoro, chloro, bromo, and iodo).
The term "haloalkyl" refers to an alkyl group as defined above in which one or more of the hydrogen atoms have been replaced with a halogen (i.e., F, Cl, Br and/or I). Thus, for example, "C1_6 haloalkyl" (or "C1-C6 haloalkyl") refers to a Ci to C6 linear or branched alkyl group as defined above with one or more halogen substituents. The term "fluoroalkyl" has an analogous meaning except the halogen substituents are restricted to fluoro.
Suitable fluoroalkyls include the series (CH2)0_4CF3 (i.e., trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoro-n-propyl, etc.).
An "aryl" is either phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl, or substituted heteroaryl, provided that substituted phenyl, substituted naphthyl, and substituted heteroaryl, each have 1 to 5 substituents independently selected from the group consisting of:
(1) C1_6 alkyl, (2) Ci_6 alkyl substituted with OH, 0-Cl -6 alkyl, 0-C1-6 haloalkyl, CN, NO2, N(RC)RD, C(0)N(RC)RD, C(0)RC, CO2RC, SRC, S(0)RC, SO2RC, SO2N(RC)RD, N(RC)C(0)RD, N(RC)CO2RD, N(RC)S02RID, N(RC)S02N(RC)RD, OC(0)N(RC)RD, N(RC)C(0)N(RC)RD, or N(RC)C(0)C(0)N(RC)RD, (3) 0-C1_6 alkyl, (4) C1-6 haloalkyl, (5) 0-C1_6 haloalkyl, (6) OH, (7) halogen, (8) CN, (9) NO2, (10) N(RC)RD, (11) C(0)N(RC)RD, (12) C(0)RC, (13) C(0)-C1_6 haloalkyl, (14) C(0)ORC, (15) OC(0)N(RC)RD, (16) SRC, (17) S(0)RC, (18) SO2RC, (19) SO2N(RC)RD, (20) N(RC)S02RD, (21) N(RC)S02N(RC)RD, (22) N(RC)C(0)RD, (23) N(RC)C(0)N(RC)RD, (24) N(RC)C(0)C(0)N(RC)RD, or (25) N(RC)CO2RD; and RC and RD are each independently H or C1_6 alkyl.
A "heteroaryl" is a (i) a 5- or 6-membered heteroaromatic ring containing from to 4 heteroatoms independently selected from N, 0 and S or (ii) a 9- or 10-membered bicyclic, fused ring system containing from 1 to 4 heteroatoms independently selected from N, 0 and S.
The atoms in a compound described herein may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present invention is meant to include all suitable isotopic variations of the compounds described herein. For example, different isotopic forms of hydrogen (H) include protium (1H) and deuterium (2H).
Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples.
Isotopically-enriched compounds described herein can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples provided herein using appropriate isotopically-enriched reagents and/or intermediates.
Compounds described herein having appropriate functional groups can be provided as salts. Examples of such compounds are described herein by reference to possible salts. Such reference is for illustration purposes, and additional embodiments include salts of any compound described herein having suitable groups.
Pharmaceutically acceptable salts can be used with compounds for treating patients. Non-pharmaceutical salts may, however, be useful in the preparation of intermediate compounds.
Pharmaceutically acceptable salts are suitable for administration to a patient, preferably, a human. Suitable salts include acid addition salts which may, for example, be formed by mixing a solution of a compound with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, or benzoic acid.
Compounds carrying an acidic moiety can be mixed with suitable pharmaceutically acceptable salts to provide, for example, alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., calcium or magnesium salts), and salts formed with suitable organic ligands such as quaternary ammonium salts. Also, in the case of an acid (-COOH) or alcohol group being present, pharmaceutically acceptable esters can be employed to modify the solubility or hydrolysis characteristics of the compound.
Intermediate Forms A first embodiment is directed to Compound 19 hydrate I, where the hydrate is characterized by an X-ray powder diffraction pattern obtained using copper Ka radiation (i.e., the radiation source is a combination of Cu Kai and Ka2 radiation), which comprises three or more characteristic peaks. Characteristic peeks are illustrated in Figure 1.
A second embodiment is directed to Compound 19 hydrate I, where the hydrate is characterized by an X-ray powder diffraction pattern obtained using copper Ka radiation which Reference to "about" with respect to 20 values provided herein indicates +
0.1.
A third embodiment is directed to Compound 19 hydrate I, where the hydrate is characterized by an X-ray powder diffraction pattern obtained using copper Ka radiation which comprises 20 values (i.e., reflections at 20 values) in degrees of about 8.7, 22.2, 23.5, 8.3, 14.7, A fourth embodiment is directed to Compound 19 hydrate I, where the hydrate is characterized by a solid state carbon-13 CPMAS NMR spectrum provided in Figure 2.
A fourth embodiment is directed to Compound 19 hydrate 1, where the hydrate is characterized by a solid state carbon-13 CPMAS NMR comprising peaks at about 174.7, 172.0, Reference to "about" with respect to the solid state carbon-13 CPMAS NMR
values provided herein indicates + 0.1.
A fifth embodiment is directed to a MeCN solvate of a Compound 14 A sixth embodiment is directed to a MeCN solvate of a Compound 14 methylsulfonic acid salt, where the solvate is characterized by an X-ray powder diffraction A seventh embodiment is directed to a MeCN solvate of a Compound 14 methylsulfonic acid salt, where the solvate is characterized by an X-ray powder diffraction pattern obtained using copper Ka radiation which comprises 20 values in degrees of about 5.3, Administration and Compositions Compounds described herein having therapeutic applications, such as Compound A, can be administered to a patient infected with HCV. The term "administration" and variants thereof (e.g., "administering" a compound) means providing the compound to the individual in need of treatment. When a compound is provided in combination with one or more other active agents (e.g., antiviral agents useful for treating HCV infection), "administration" and its variants are each understood to include concurrent and sequential provision of the compound or salt and other agents.
As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients, as well as any product which results, directly or indirectly, from combining the specified ingredients.
By "pharmaceutically acceptable" is meant the ingredients of the pharmaceutical composition are compatible with each other and are suitable to the recipient thereof.
The term "subject" (alternatively referred to herein as "patient") as used herein refers to an animal, preferably a mammal, most preferably a human, who is the object of treatment, observation or experiment.
The term "effective amount" indicates a sufficient amount to exert a therapeutic or prophylactic effect. For a patient infected with HCV, an effective amount is sufficient to achieve one or more of the following effects: reduce the ability of HCV to replicate, reduce HCV load, and increase viral clearance. For a patient not infected with HCV, an effective amount is sufficient to achieve one or more of the following: a reduced susceptibility to HCV infection, and a reduced ability of the infecting virus to establish persistent infection for chronic disease.
For the purpose of inhibiting HCV NS3 protease and treating HCV infection and/or reducing the likelihood or severity of symptoms of HCV infection, the compounds, optionally in the form of a salt, can be administered by means that produces contact of the active agent with the agent's site of action. They can be administered by conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but typically are administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
Compounds can, for example, be administered by one or more of the following routes: oral, parenteral (including subcutaneous injections, intravenous, intramuscular.
intrastemal injection or infusion techniques), by inhalation (such as in a spray form), or rectal, in the form of a unit dosage of a pharmaceutical composition containing an effective amount of the compound and pharmaceutically-acceptable carrier (e.g., a carrier suitable for administration to a human patient), adjuvants and vehicles. Liquid preparations suitable for oral administration (e.g., suspensions, syrups, elixirs and the like) can employ media such as water, glycols, oils, alcohols and the like. Solid preparations suitable for oral administration (e.g., powders, pills, capsules and tablets) can employ solid excipients as such starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like. Parenteral compositions typically employ sterile water as a carrier and optionally other ingredients, such as solubility aids.
Injectable solutions can be prepared, for example, using a carrier comprising a saline solution, a glucose solution or a solution containing a mixture of saline and glucose. Further guidance for methods suitable for use in preparing pharmaceutical compositions is provided in Remington: The Science and Practice of Pharmacy, 21th edition (Lippincott Williams & Wilkins, 2006).
Therapeutic compounds can be administered orally in a dosage range of 0.001 to 1000 mg/kg of mammal (e.g., human) body weight per day in a single dose or in divided doses.
One dosage range is 0.01 to 500 mg/kg body weight per day orally in a single dose or in divided doses. Another dosage range is 0.1 to 100 mg/kg body weight per day orally in single or divided doses. For oral administration, the compositions can be provided in the form of tablets or capsules containing 1.0 to 500 mg of the active ingredient, particularly 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500, and 750 mg of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. The specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
HCV Inhibitory Activity The ability of a compound to inhibit HCV NS3 activity, HCV replicon activity, and HCV replication activity can be evaluated using techniques well-known in the art. (See, for example, Carroll etal., I Biol. Chem. 278:11979-11984, 2003.) One such assay is a HCV NS3 protease time-resolved fluorescence (TRF) assay as described below and in Mao etal., Anal. Biochem. 3 73:1-8, 2008 and Mao etal., WO 2006/102087. A NS3 protease assay can be performed, for example, in a final volume of 100 [11 assay buffer containing 50 mM HEPES, pH 7.5, 150 mM NaC1, 15 %
glycerol, 0.15 %
TRITON X-100, 10 mM DTT, and 0.1 % PEG 8000. NS3 and NS4A are pre-incubated with various concentrations of inhibitors in DMSO for 30 minutes. The reaction is initiated by adding the TRF peptide substrate (final concentration 100 nM). NS3 mediated hydrolysis of the substrate is quenched after 1 hour at room temperature with 100 1 of 500 mM
MES, pH 5.5.
Product fluorescence is detected using either a VICTOR V2 or FUSION
fluorophotometer (Perkin Elmer Life and Analytical Sciences) with excitation at 340 nm and emission at 615 nm with a 400 is delay. Testing concentrations of different enzyme forms are selected to result in a signal to background ratio (S/B) of 10-30. IC50 values are derived using a standard four-parameter fit to the data. K, values are derived from IC50 values using the following formula, IC50 = K, (1 + [S] / KO, Eqn (1), where [S] is the concentration of substrate peptide in the reaction and Km is the Michaelis constant. See P. Gallinari et al., 38 BIOCHEM. 5620-32(1999); P. Gallinari et al., 72 J. VIROL.
6758-69 (1998); M. Taliani etal., 240 ANAL. BIOCHEM. 60-67 (1996); and Mao etal., Analytical Biochemistry 373: 1-8, (2008).
Abbreviations BOC: t-Butoxycarbonyl Cbz: Benzyloxycarbonyl CDI: 1,1'-Carbonyldiimidazole CIP: 2-Chluoro-1-methylpyridinium iodide CPME: Cyclopentyl methyl ether DABO: 1,4-Diazabicyclo [2.2.2.1 octane DBA saltdibenzylamine DBU: 1,8-Diazobicyclo[5.4.01undec-7-ene DCC: N,N1-Dicyclohexylcarbodiimide DIC: /V,AP-diisopropylcarbodiimide DIPEA: Diisopropylethylamine DMAc: N,N-Dimethylacetamide DMF: N,N-Dimethylformamide DMPU: N,N-dimethylpropyleneurea DMSO: Dimethylsulfoxide EDC: 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide Et0Ac: Ethyl acetate Fmoc: 9-Fluorenylmethyloxycarbonyl HATU: 2-(1H-7-Azabenzotriazole-1-y1)-1,1,3,3-tetramethyluronium hexafluorophosphate HOBT: 1-Hydroxybenzotriazole HOPO: 2-Hydroxypyridine-N-oxide HOSu: N-hydroxysuccinimide IPA: Isopropanol MTBE: t-butyl methyl ether Ms0H and MSA: CH3S03H or methanesulfonic acid Moz: p-Methoxybenzyloxycarbonyl Msz: 4-Methylsulfinylbenzyloxycarbonyl PFP: pentafluorophenol T3P: propylphosphonic anhydride TBA: t-butyl amine TEA: Triethylamine pTSA and Ts0H are each abbreviations for p-toluenesulfonic acid.
Examples The examples provided below are intended to illustrate the invention and its 25 practice. Unless otherwise provided in the claims, the examples are not to be construed as limitations on the scope or spirit of the invention.
Example 1: Preparation of 242-(3-Chloro-propy1)-cyclopropy1]-4,4,5,5-tetramethyl-L1,3,2]dioxaborolane (Compound 3) 1. ZnEt2, TFA, CH2I2 CI131 z< DCM, 0 C - RT
2. 1 M HCI
Compound 2 can be prepared as described by Shirakawa et al. Synthesis 11:1814-1820, 2004.) Compound 3 was produced as follows: To a 5 L flask equipped with a nitrogen Example 2: Preparation of 2-(3-Chloro-propv1)-cyclopropanol (Compound 4).
NaOH, H202 Me0H, 0 C-RT )1.
To a 3 L flask equipped with a nitrogen inlet, mechanical stirrer, dropping funnel and thermocouple was added 143 g of 3 (0.585 mol, 1.0 equiv) in 1 L methanol.
To the flask was then added from the dropping funnel 58.5 mL of 10 M sodium hydroxide (0.585 mol, 1.0 equiv) over 30 min, while the internal temperature was maintained below 10 C with external cooling.
After stirring for 30 min, 120 mL of 30 wt% hydrogen peroxide solution (1.17 mol, 2 equiv) was slowly added from the dropping funnel over 1 hour, keeping the internal temperature below 10 C. Upon completion of the addition, the resulting colorless slurry was then stirred at ambient temperature for 30 min or until complete consumption of 3 was observed by GC.
2 M HC1 (375 mL) was added from the dropping funnel over 30 mm, keeping the internal temperature below 10 C. To this clear yellow solution was then slowly added 500 mL of a 1 M
solution of Na2S03 from the dropping funnel, keeping the internal temperature below 10 C. The resulting suspension was then filtered and extracted 3 x 200 mL MTBE. Concentration followed by silica gel column chromatography (6:4 hexane:ethyl acetate), to remove pinacol, gave 60.6 g of product 4 as a clear oil (90 wt %). 1HNMR (400 MHz, CDC13) 8 3.62 (t, 2H, J=
6.6 Hz), 3.27 (dt, 1H, J= 6.3, 2.6 Hz), 1.89 (pent, 2H, J= 6.8 Hz), 1.85 (bs, OH), 1.43 (sext, 1H, J= 7.0 Hz), 1.28 (sext, 1H, J- 7.0 Hz), 0.94 (m, 1H), 0.75 (m, 1H), 0.38 (q, 111, J= 6.0 Hz); 13C NMR (100 MHz, CDC13) 8 52.21, 44.69, 31.91, 28.69, 19.69, 14.15; GC: HP1 (30 m x 0.32 mm; 0.25 xm), psi, 200 C front inlet. 5 min @ 50 C, ramp 25 / min to 250 C then hold for 4 min, tr(3)=10.08 min, -4(4)=7.15 min.
Example 3: Preparation of 2-Pent-4-ynyl-cyclopropanol (rac-Compound 5) 1. n-HexLi, THE, 0 C
">*OH
2. HCECLi = H2N---""'NH2 4 rac-5 DMPU, RT-50 C
To a 2-neck 15-mL flask equipped with a temperature probe, N2 inlet, and septum was added 1 g of 4 (7.28 mmol, 1.0 equiv) and 3.0 mL THE The solution was cooled to an internal temperature of 0 C with an ice bath. To this solution was added 2.95 mL of 33 wt% n-Hexyllithium (7.28 mmol, 1.0 equiv) slowly via syringe pump over 1 hour.
Internal temperature rose to 6.8 C and solution became yellow. In a separate 3-neck 100-mL flask equipped with a temperature probe, N2 inlet, and septum 0.82 g of lithium acetylide-ethylenediamine complex (8.01 mmol, 1.1 equiv) was slurried in 5.0 mL of DMPU at room temperature. To this room temperature slurry, the cold solution of the deprotonated cyclopropanol was transferred via cannula over 5 min. After the addition, the brown mixture was heated to an internal temperature of 52 C with a heating mantle for 3 hours or until greater than 98%
conversion was observed by GC. The brown mixture was cooled with an ice bath to 3 C and then the ice bath was removed to prevent freezing. To this was slowly added 17.5 mL of 0.5 N HC1 and an ice bath was applied to maintain an internal temperature below 21 C. The mixture was then diluted with 10 mL
MTBE and 5 mL of water before transfer to a separatory funnel and removal of the aqueous layer. The aqueous layer was extracted once with 15 mL MTBE and then the combined organic layers were washed with 20 mL water followed by 20 mL brine. The organic layer was then concentrated in vacuo to afford 1.27 g of rac-5 as a yellow oil (72 wt%). 111 NMR (400 MHz, CDC13) 8 3.24 (dt, 1H, .J= 2.6, 5.3 Hz), 2.25 (dt, 2H, J= 2.6, 7.6 Hz), 1.96 (t, 111, J = 2.6 Hz), 1.92 (s, 1H, OH), 1.64 (pent, 2H, J= 7.3 Hz), 1.38 (sext, 1H, J= 6.9 Hz), 1.24 (sext, 1H, J = 6.9 Hz), 0.93 (m, 1H), 0.72 (m, 1H), 0.35 (q, 1H, J = 6.0 Hz); 13C NMR (100 MHz, CDC13) 8 84.49, 68.37, 52.45, 30.50, 27.74, 20.17, 18.01, 14.25; GC: HP1 (30 m x 0.32 mm; 0.25 11m), 25 psi, 200 C front inlet. 5 min @ 50 C, ramp 25 C / mm to 250 C then hold for 4 min, t1(4) = 7.15 min, tr(rac-5) = 6.72 min.
Example 4: Preparation of Acetic Acid racemic trans-2-pent-4-ynyl-cyclopropyl ester (rac-Compound 6) OH AcCI, NEt3 0 Me A
MTBE
rac-5 rac-6 To a 5L flask equipped with a nitrogen inlet, mechanical stirrer, dropping funnel and thermocouple under N2 was added 31.2 g of rac-5 (251 mmol, 1.0 equiv), 350 mL of MTBE
and 45.5 mL of triethylamine (327 mmol, 1.3 equiv) prior to cooling the solution in an acetone/ice bath to an internal temp of < 5 C. To the solution was added from the dropping funnel 23.7 mL acetyl chloride (301 mmol, 1.1 equiv) over a 30 min period while maintaining the internal temp <10 C. The resulting slurry was then warmed to room temperature and aged for 2 hours. The reaction mixture was then diluted with 200 mL of water. The organic layer was washed with 200 mL of 2 N HC1 and then with 300 mL of sat. NaHCO3 prior to drying over MgSO4. The solvent was removed in vacuo to give 41.8 g of rac-6. 1HNMR (400 MHz, CDC13) 8 3.84 (dt, 111, J = 6.7, 2.9 Hz), 2.25 (dt, 2H, J= 2.7, 7.0 Hz), 2.03 (s, 3H), 1.95 (t, 1H, J= 2.6 Novozym 435 0 0.1M pH 7 buffer 0 OH +
MTBE, 10 C
rac-6 ent-5 ent-6 To a 1-L flask equipped with an overhead stirrer and temperature probe was added a 60 wt% solution of rac-6 in MTBE (44.8 g, 0.27 mol) and an additional 730 ml of MTBE that had been saturated with aqueous 0.1 M pH 7 phosphate buffer, giving a final solution temperature of approximately 10 C throughout the hydrolysis reaction, which was initiated by the addition of 730 mg Novozym 435. The reaction was aged at 10 C for approximately 4 hours until conversion had reached 41%, at which point the ee of ent-5 was 96%. The reaction mixture was then filtered through a 150-ml medium-pore glass filter funnel and the solid immobilized solvent switched to heptane. The mixture in heptane (39.2 kg, approximately 50 L) was applied to a Biotage Flash 400 L cartridge (40 x 60 cm, 40 kg silica gel, 60 angstrom, 40-63 um) and eluted sequentially with 165 L of 2.5:97.5, 75 L of 10:90, and 330 L of 25:75 Et0Ac/heptane (v/v). After the mixture was applied to the column, 18 L fractions were taken.
The rich cut analyzed by GC (HP-1, 30 m x 320 um x 0.25 urn film, 9.14 psi constant He pressure, 15:1 split, 50 C for 5 min then 25 deg/min to 275 C and hold 5 min, RT of alcohol 8.8 min). Fractions 15-21 were concentrated to give 3.48 kg (80 wt%, 92 %ee) of the desired ent-5 (Compound 7).
GC: Restek RT-Bdex SA (30 m x 0.25mm x 0.25 pm), 60 cm/s linear velocity, Example 6: Preparation of (S)-3,3-Dimethy1-24(1R,2R)-2-pent-4-ynyl-cyclopropoxycarbonylamino)-butyric acid (Compound 8) OH
1. CDI, Hunigs Base OAN CO2H
H
2.
To a 50L round bottom flask equipped with a mechanical stirrer, thermocouple and reflux condenser was added Compound 7 (3.477 kg @ 81 wt% by NMR, 92 % ee) and 14.1 L (5 L/kg) of Hunigs base. To the resulting homogeneous solution was added CDI
portion wise as a solid while maintaining the internal temperature between 21-25 C. The resulting slurry was aged at room temperature for 1 hour. To the slurry was added L-tert-leucine as a solid and the reaction mixture was heated to an internal temperature of 95 C for 2.5 hours.
The reaction mixture was cooled to room temperature and diluted with 17 L of water. The mixture was aged for 30 min to dissolve all the solids and then transferred to a 100 L
cylindrical extractor. The aqueous layer was then washed with 12 L of MTBE. The aqueous layer was washed with 8 L of MTBE. The resulting aqueous layer was pH adjusted with concentrated HCl to a final pH of 1.5-2Ø The biphasic mixture was extracted with MTBE (2 X 12 L) and the combined organic phase was washed with 6 L of water followed by 5 L of brine.
The MTBE layer was then transferred via vacuum into a 50 L round bottom flask equipped with a mechanical stirrer, thermocouple, and batch concentrator and the solvent was removed under reduced pressure keeping the internal temperature of the batch <20 C during the distillation. The solvent was then switched to cyclopentyl methyl ether (CPME) by flushing with ¨ 5 L of CPME and then diluted to a final volume of ¨ 20 L. This material was used in the next reaction without further purification.
An analytical sample was obtained by silica gel chromatography as a colorless oil: II-1 NMR (CDC13, 400 MHz) 60.54 (q, 11-1, J= 6.4 Hz), 0.83 (m, 1H), 0.99 (m, 111), 1.01 (s, 9H), 1.40 (m, 2H), 1.67 (m, 2H), 1.94 (t. 1H, J= 2.6 Hz), 2.23 (m, 2H), 3.77 (br m, 111), 4.20 (br m, 1I-1), 5.28 (br m, 1H), 9.40 (br s, 1H); I3C NMR (CDC13, 100 MHz) 6 11.8, 18.0, 26.5, 27.4, 30.1, 34.6, 55.0, 62.0, 68.4, 84.2, 156.7, 175.8.
The reaction can be carried out by SNAR replacement of Compound 11 with Compound 12 in the presence of a base. Compound 11 is described by Sarges et al., J. Med.
Chem. 33:2240-2254, 1990. A general temperature for the reaction is 20-100 C, with a preferred temperature being 40-45 C. A wide range of solvents can be using including aprotic polar solvents, DMF, DMAc, NMP, DMSO, and DMPU. A preferred solvent is DMAc.
Different bases can be used including Cs2CO3, DBU, K2CO3, K3PO4, and KOtBu. A
preferred base is DBU. An advantage of the reaction was high regioselectivity and no detected isomerization of the hydroxyproline.
Deprotection can be carried out with various acids including pTSA, PhS03H, MeS03H, HC1, H2SO4, HBr, Ac0H-HC1 in a wide range solvents including IPAc, Et0Ac, MeCN, and DMAc. The use of methansulfonic acid in MeCN is preferred allowing direct isolation of Compound 14 as a MeCN solvate MeS03I1 salt from the reaction mixture. A general temperature for the reaction is 0-80 C, with a preferred temperature being ¨40 C.
Examples of combinations of upstream and downstream steps include methods comprising: Aspects 1, 3, 4 and 6; Aspects 2, 3, 4 and 6; Aspects 4, 5 and 6;
and subsets within these combinations. Methods directed to subsets comprising adjacent steps, or a series of adjacent steps. For examples, subsets within the combination of Aspects 1, 3, 4 and 6, include a method comprising 1 and 3; 1, 3, and 4; 1, 3, 4, and 6; 6 and 1; 3 and 4; and so forth.
Compound A
Another aspect is directed to method of making Compound A comprising the step of coupling:
ioi OMe N
f)yN
/C)C-= 02H Fi2NN.S.,,,v 0 \tf iFµL N S:" H
\
Compound 20 Compound 19 or salt thereof, to or salt thereof, to form Compound A or salt thereof, wherein the coupling comprises the use of a coupling reagent and pyridine or a pyridine derivative.
Preferably, no detectable HOBt is present. The reaction can be carried out using a coupling reagent, an aprotic organic solvent and pyridine or a pyridine derivative. A general temperature is -10 C to 50 C (preferably 0 to 20 C). Examples of coupling reagents include dicyclohexylcarbodiimide (DCC), N,N'-diisopropylcarbodiimide (DIC), and 1-ethy1-3-(3-dimethylaminopropyl) carbodiimide (EDC), and HATU. Examples of aprotic organic solvents include acetonitrile, THF, THF-DMAc, THF-DMF, THF-NMP, and toluene. In an embodiment, THF-DMAc or THF is used.
In different embodiments EDC is used; EDC is used along pyridine and acetonitrile; EDC is used along with at least 10 equivalents of pyridine and acetonitrile; and EDC
is used along with pyridine and THF-DMAc.
In an embodiment, directed to using EDC with THF-DMAc, Compound 19 hydrate is azeotropically dried in THF, and combined with Compound 20 and DMAc, followed by addition of pyridine or a pyridine derivative and EDC. A preferred temperature range is from about 0 C to 20 C, preferably at 0-5 C for 1 hour followed by 15-20 C for additional 1-2 hours. The use of reaction conditions employing THF-DMAc or THF in conjunction with EDC
facilitates control of the reaction profile and suppression of the formation of by-products, for example, by reducing the over reaction of coupling agent. Alternative procedures could result in significant over reaction of coupling agent with compound A in the absence of quenching.
In an embodiment, Compound 20 used in this aspect, including any of the embodiments, is pTSA salt.
Preferred pyridine derivatives have electron donating or neutral groups at the and 4 position. Examples of general structures covering pyridine and derivatives include:
N
wherein R5 is either hydrogen, aryl, halogen, C1-6 alkyl, 0-C1-6 alkyl or C3-cycloalkyl. Preferred reagents are pyridine, 4-phenylpyridine, 4-alkylpyridine, methylpyridine, 3- or 4- mono or dialkylpyridine, wherein the alkyl group can be a C1-6 alkyl.
Compounds The term "alkyl" refers to a monovalent straight or branched chain, saturated aliphatic hydrocarbon radical having a number of carbon atoms in the specified range. Thus, for example, "C1-6 alkyl" refers to any of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and t-butyl, n- and iso- propyl, ethyl, and methyl. As another example, "Ci 4 alkyl"
refers to n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl, and methyl.
The term "cycloalkyl" refers to any monocyclic ring of an alkane having a number of carbon atoms in the specified range. Thus, for example, "C3_8 cycloalkyl" (or "C3-C8 cycloalkyl") refers to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
The term "halogen" (or "halo") refers to fluorine, chlorine, bromine and iodine (alternatively referred to as fluoro, chloro, bromo, and iodo).
The term "haloalkyl" refers to an alkyl group as defined above in which one or more of the hydrogen atoms have been replaced with a halogen (i.e., F, Cl, Br and/or I). Thus, for example, "C1_6 haloalkyl" (or "C1-C6 haloalkyl") refers to a Ci to C6 linear or branched alkyl group as defined above with one or more halogen substituents. The term "fluoroalkyl" has an analogous meaning except the halogen substituents are restricted to fluoro.
Suitable fluoroalkyls include the series (CH2)0_4CF3 (i.e., trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoro-n-propyl, etc.).
An "aryl" is either phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl, or substituted heteroaryl, provided that substituted phenyl, substituted naphthyl, and substituted heteroaryl, each have 1 to 5 substituents independently selected from the group consisting of:
(1) C1_6 alkyl, (2) Ci_6 alkyl substituted with OH, 0-Cl -6 alkyl, 0-C1-6 haloalkyl, CN, NO2, N(RC)RD, C(0)N(RC)RD, C(0)RC, CO2RC, SRC, S(0)RC, SO2RC, SO2N(RC)RD, N(RC)C(0)RD, N(RC)CO2RD, N(RC)S02RID, N(RC)S02N(RC)RD, OC(0)N(RC)RD, N(RC)C(0)N(RC)RD, or N(RC)C(0)C(0)N(RC)RD, (3) 0-C1_6 alkyl, (4) C1-6 haloalkyl, (5) 0-C1_6 haloalkyl, (6) OH, (7) halogen, (8) CN, (9) NO2, (10) N(RC)RD, (11) C(0)N(RC)RD, (12) C(0)RC, (13) C(0)-C1_6 haloalkyl, (14) C(0)ORC, (15) OC(0)N(RC)RD, (16) SRC, (17) S(0)RC, (18) SO2RC, (19) SO2N(RC)RD, (20) N(RC)S02RD, (21) N(RC)S02N(RC)RD, (22) N(RC)C(0)RD, (23) N(RC)C(0)N(RC)RD, (24) N(RC)C(0)C(0)N(RC)RD, or (25) N(RC)CO2RD; and RC and RD are each independently H or C1_6 alkyl.
A "heteroaryl" is a (i) a 5- or 6-membered heteroaromatic ring containing from to 4 heteroatoms independently selected from N, 0 and S or (ii) a 9- or 10-membered bicyclic, fused ring system containing from 1 to 4 heteroatoms independently selected from N, 0 and S.
The atoms in a compound described herein may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present invention is meant to include all suitable isotopic variations of the compounds described herein. For example, different isotopic forms of hydrogen (H) include protium (1H) and deuterium (2H).
Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples.
Isotopically-enriched compounds described herein can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples provided herein using appropriate isotopically-enriched reagents and/or intermediates.
Compounds described herein having appropriate functional groups can be provided as salts. Examples of such compounds are described herein by reference to possible salts. Such reference is for illustration purposes, and additional embodiments include salts of any compound described herein having suitable groups.
Pharmaceutically acceptable salts can be used with compounds for treating patients. Non-pharmaceutical salts may, however, be useful in the preparation of intermediate compounds.
Pharmaceutically acceptable salts are suitable for administration to a patient, preferably, a human. Suitable salts include acid addition salts which may, for example, be formed by mixing a solution of a compound with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, or benzoic acid.
Compounds carrying an acidic moiety can be mixed with suitable pharmaceutically acceptable salts to provide, for example, alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., calcium or magnesium salts), and salts formed with suitable organic ligands such as quaternary ammonium salts. Also, in the case of an acid (-COOH) or alcohol group being present, pharmaceutically acceptable esters can be employed to modify the solubility or hydrolysis characteristics of the compound.
Intermediate Forms A first embodiment is directed to Compound 19 hydrate I, where the hydrate is characterized by an X-ray powder diffraction pattern obtained using copper Ka radiation (i.e., the radiation source is a combination of Cu Kai and Ka2 radiation), which comprises three or more characteristic peaks. Characteristic peeks are illustrated in Figure 1.
A second embodiment is directed to Compound 19 hydrate I, where the hydrate is characterized by an X-ray powder diffraction pattern obtained using copper Ka radiation which Reference to "about" with respect to 20 values provided herein indicates +
0.1.
A third embodiment is directed to Compound 19 hydrate I, where the hydrate is characterized by an X-ray powder diffraction pattern obtained using copper Ka radiation which comprises 20 values (i.e., reflections at 20 values) in degrees of about 8.7, 22.2, 23.5, 8.3, 14.7, A fourth embodiment is directed to Compound 19 hydrate I, where the hydrate is characterized by a solid state carbon-13 CPMAS NMR spectrum provided in Figure 2.
A fourth embodiment is directed to Compound 19 hydrate 1, where the hydrate is characterized by a solid state carbon-13 CPMAS NMR comprising peaks at about 174.7, 172.0, Reference to "about" with respect to the solid state carbon-13 CPMAS NMR
values provided herein indicates + 0.1.
A fifth embodiment is directed to a MeCN solvate of a Compound 14 A sixth embodiment is directed to a MeCN solvate of a Compound 14 methylsulfonic acid salt, where the solvate is characterized by an X-ray powder diffraction A seventh embodiment is directed to a MeCN solvate of a Compound 14 methylsulfonic acid salt, where the solvate is characterized by an X-ray powder diffraction pattern obtained using copper Ka radiation which comprises 20 values in degrees of about 5.3, Administration and Compositions Compounds described herein having therapeutic applications, such as Compound A, can be administered to a patient infected with HCV. The term "administration" and variants thereof (e.g., "administering" a compound) means providing the compound to the individual in need of treatment. When a compound is provided in combination with one or more other active agents (e.g., antiviral agents useful for treating HCV infection), "administration" and its variants are each understood to include concurrent and sequential provision of the compound or salt and other agents.
As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients, as well as any product which results, directly or indirectly, from combining the specified ingredients.
By "pharmaceutically acceptable" is meant the ingredients of the pharmaceutical composition are compatible with each other and are suitable to the recipient thereof.
The term "subject" (alternatively referred to herein as "patient") as used herein refers to an animal, preferably a mammal, most preferably a human, who is the object of treatment, observation or experiment.
The term "effective amount" indicates a sufficient amount to exert a therapeutic or prophylactic effect. For a patient infected with HCV, an effective amount is sufficient to achieve one or more of the following effects: reduce the ability of HCV to replicate, reduce HCV load, and increase viral clearance. For a patient not infected with HCV, an effective amount is sufficient to achieve one or more of the following: a reduced susceptibility to HCV infection, and a reduced ability of the infecting virus to establish persistent infection for chronic disease.
For the purpose of inhibiting HCV NS3 protease and treating HCV infection and/or reducing the likelihood or severity of symptoms of HCV infection, the compounds, optionally in the form of a salt, can be administered by means that produces contact of the active agent with the agent's site of action. They can be administered by conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but typically are administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
Compounds can, for example, be administered by one or more of the following routes: oral, parenteral (including subcutaneous injections, intravenous, intramuscular.
intrastemal injection or infusion techniques), by inhalation (such as in a spray form), or rectal, in the form of a unit dosage of a pharmaceutical composition containing an effective amount of the compound and pharmaceutically-acceptable carrier (e.g., a carrier suitable for administration to a human patient), adjuvants and vehicles. Liquid preparations suitable for oral administration (e.g., suspensions, syrups, elixirs and the like) can employ media such as water, glycols, oils, alcohols and the like. Solid preparations suitable for oral administration (e.g., powders, pills, capsules and tablets) can employ solid excipients as such starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like. Parenteral compositions typically employ sterile water as a carrier and optionally other ingredients, such as solubility aids.
Injectable solutions can be prepared, for example, using a carrier comprising a saline solution, a glucose solution or a solution containing a mixture of saline and glucose. Further guidance for methods suitable for use in preparing pharmaceutical compositions is provided in Remington: The Science and Practice of Pharmacy, 21th edition (Lippincott Williams & Wilkins, 2006).
Therapeutic compounds can be administered orally in a dosage range of 0.001 to 1000 mg/kg of mammal (e.g., human) body weight per day in a single dose or in divided doses.
One dosage range is 0.01 to 500 mg/kg body weight per day orally in a single dose or in divided doses. Another dosage range is 0.1 to 100 mg/kg body weight per day orally in single or divided doses. For oral administration, the compositions can be provided in the form of tablets or capsules containing 1.0 to 500 mg of the active ingredient, particularly 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500, and 750 mg of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. The specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
HCV Inhibitory Activity The ability of a compound to inhibit HCV NS3 activity, HCV replicon activity, and HCV replication activity can be evaluated using techniques well-known in the art. (See, for example, Carroll etal., I Biol. Chem. 278:11979-11984, 2003.) One such assay is a HCV NS3 protease time-resolved fluorescence (TRF) assay as described below and in Mao etal., Anal. Biochem. 3 73:1-8, 2008 and Mao etal., WO 2006/102087. A NS3 protease assay can be performed, for example, in a final volume of 100 [11 assay buffer containing 50 mM HEPES, pH 7.5, 150 mM NaC1, 15 %
glycerol, 0.15 %
TRITON X-100, 10 mM DTT, and 0.1 % PEG 8000. NS3 and NS4A are pre-incubated with various concentrations of inhibitors in DMSO for 30 minutes. The reaction is initiated by adding the TRF peptide substrate (final concentration 100 nM). NS3 mediated hydrolysis of the substrate is quenched after 1 hour at room temperature with 100 1 of 500 mM
MES, pH 5.5.
Product fluorescence is detected using either a VICTOR V2 or FUSION
fluorophotometer (Perkin Elmer Life and Analytical Sciences) with excitation at 340 nm and emission at 615 nm with a 400 is delay. Testing concentrations of different enzyme forms are selected to result in a signal to background ratio (S/B) of 10-30. IC50 values are derived using a standard four-parameter fit to the data. K, values are derived from IC50 values using the following formula, IC50 = K, (1 + [S] / KO, Eqn (1), where [S] is the concentration of substrate peptide in the reaction and Km is the Michaelis constant. See P. Gallinari et al., 38 BIOCHEM. 5620-32(1999); P. Gallinari et al., 72 J. VIROL.
6758-69 (1998); M. Taliani etal., 240 ANAL. BIOCHEM. 60-67 (1996); and Mao etal., Analytical Biochemistry 373: 1-8, (2008).
Abbreviations BOC: t-Butoxycarbonyl Cbz: Benzyloxycarbonyl CDI: 1,1'-Carbonyldiimidazole CIP: 2-Chluoro-1-methylpyridinium iodide CPME: Cyclopentyl methyl ether DABO: 1,4-Diazabicyclo [2.2.2.1 octane DBA saltdibenzylamine DBU: 1,8-Diazobicyclo[5.4.01undec-7-ene DCC: N,N1-Dicyclohexylcarbodiimide DIC: /V,AP-diisopropylcarbodiimide DIPEA: Diisopropylethylamine DMAc: N,N-Dimethylacetamide DMF: N,N-Dimethylformamide DMPU: N,N-dimethylpropyleneurea DMSO: Dimethylsulfoxide EDC: 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide Et0Ac: Ethyl acetate Fmoc: 9-Fluorenylmethyloxycarbonyl HATU: 2-(1H-7-Azabenzotriazole-1-y1)-1,1,3,3-tetramethyluronium hexafluorophosphate HOBT: 1-Hydroxybenzotriazole HOPO: 2-Hydroxypyridine-N-oxide HOSu: N-hydroxysuccinimide IPA: Isopropanol MTBE: t-butyl methyl ether Ms0H and MSA: CH3S03H or methanesulfonic acid Moz: p-Methoxybenzyloxycarbonyl Msz: 4-Methylsulfinylbenzyloxycarbonyl PFP: pentafluorophenol T3P: propylphosphonic anhydride TBA: t-butyl amine TEA: Triethylamine pTSA and Ts0H are each abbreviations for p-toluenesulfonic acid.
Examples The examples provided below are intended to illustrate the invention and its 25 practice. Unless otherwise provided in the claims, the examples are not to be construed as limitations on the scope or spirit of the invention.
Example 1: Preparation of 242-(3-Chloro-propy1)-cyclopropy1]-4,4,5,5-tetramethyl-L1,3,2]dioxaborolane (Compound 3) 1. ZnEt2, TFA, CH2I2 CI131 z< DCM, 0 C - RT
2. 1 M HCI
Compound 2 can be prepared as described by Shirakawa et al. Synthesis 11:1814-1820, 2004.) Compound 3 was produced as follows: To a 5 L flask equipped with a nitrogen Example 2: Preparation of 2-(3-Chloro-propv1)-cyclopropanol (Compound 4).
NaOH, H202 Me0H, 0 C-RT )1.
To a 3 L flask equipped with a nitrogen inlet, mechanical stirrer, dropping funnel and thermocouple was added 143 g of 3 (0.585 mol, 1.0 equiv) in 1 L methanol.
To the flask was then added from the dropping funnel 58.5 mL of 10 M sodium hydroxide (0.585 mol, 1.0 equiv) over 30 min, while the internal temperature was maintained below 10 C with external cooling.
After stirring for 30 min, 120 mL of 30 wt% hydrogen peroxide solution (1.17 mol, 2 equiv) was slowly added from the dropping funnel over 1 hour, keeping the internal temperature below 10 C. Upon completion of the addition, the resulting colorless slurry was then stirred at ambient temperature for 30 min or until complete consumption of 3 was observed by GC.
2 M HC1 (375 mL) was added from the dropping funnel over 30 mm, keeping the internal temperature below 10 C. To this clear yellow solution was then slowly added 500 mL of a 1 M
solution of Na2S03 from the dropping funnel, keeping the internal temperature below 10 C. The resulting suspension was then filtered and extracted 3 x 200 mL MTBE. Concentration followed by silica gel column chromatography (6:4 hexane:ethyl acetate), to remove pinacol, gave 60.6 g of product 4 as a clear oil (90 wt %). 1HNMR (400 MHz, CDC13) 8 3.62 (t, 2H, J=
6.6 Hz), 3.27 (dt, 1H, J= 6.3, 2.6 Hz), 1.89 (pent, 2H, J= 6.8 Hz), 1.85 (bs, OH), 1.43 (sext, 1H, J= 7.0 Hz), 1.28 (sext, 1H, J- 7.0 Hz), 0.94 (m, 1H), 0.75 (m, 1H), 0.38 (q, 111, J= 6.0 Hz); 13C NMR (100 MHz, CDC13) 8 52.21, 44.69, 31.91, 28.69, 19.69, 14.15; GC: HP1 (30 m x 0.32 mm; 0.25 xm), psi, 200 C front inlet. 5 min @ 50 C, ramp 25 / min to 250 C then hold for 4 min, tr(3)=10.08 min, -4(4)=7.15 min.
Example 3: Preparation of 2-Pent-4-ynyl-cyclopropanol (rac-Compound 5) 1. n-HexLi, THE, 0 C
">*OH
2. HCECLi = H2N---""'NH2 4 rac-5 DMPU, RT-50 C
To a 2-neck 15-mL flask equipped with a temperature probe, N2 inlet, and septum was added 1 g of 4 (7.28 mmol, 1.0 equiv) and 3.0 mL THE The solution was cooled to an internal temperature of 0 C with an ice bath. To this solution was added 2.95 mL of 33 wt% n-Hexyllithium (7.28 mmol, 1.0 equiv) slowly via syringe pump over 1 hour.
Internal temperature rose to 6.8 C and solution became yellow. In a separate 3-neck 100-mL flask equipped with a temperature probe, N2 inlet, and septum 0.82 g of lithium acetylide-ethylenediamine complex (8.01 mmol, 1.1 equiv) was slurried in 5.0 mL of DMPU at room temperature. To this room temperature slurry, the cold solution of the deprotonated cyclopropanol was transferred via cannula over 5 min. After the addition, the brown mixture was heated to an internal temperature of 52 C with a heating mantle for 3 hours or until greater than 98%
conversion was observed by GC. The brown mixture was cooled with an ice bath to 3 C and then the ice bath was removed to prevent freezing. To this was slowly added 17.5 mL of 0.5 N HC1 and an ice bath was applied to maintain an internal temperature below 21 C. The mixture was then diluted with 10 mL
MTBE and 5 mL of water before transfer to a separatory funnel and removal of the aqueous layer. The aqueous layer was extracted once with 15 mL MTBE and then the combined organic layers were washed with 20 mL water followed by 20 mL brine. The organic layer was then concentrated in vacuo to afford 1.27 g of rac-5 as a yellow oil (72 wt%). 111 NMR (400 MHz, CDC13) 8 3.24 (dt, 1H, .J= 2.6, 5.3 Hz), 2.25 (dt, 2H, J= 2.6, 7.6 Hz), 1.96 (t, 111, J = 2.6 Hz), 1.92 (s, 1H, OH), 1.64 (pent, 2H, J= 7.3 Hz), 1.38 (sext, 1H, J= 6.9 Hz), 1.24 (sext, 1H, J = 6.9 Hz), 0.93 (m, 1H), 0.72 (m, 1H), 0.35 (q, 1H, J = 6.0 Hz); 13C NMR (100 MHz, CDC13) 8 84.49, 68.37, 52.45, 30.50, 27.74, 20.17, 18.01, 14.25; GC: HP1 (30 m x 0.32 mm; 0.25 11m), 25 psi, 200 C front inlet. 5 min @ 50 C, ramp 25 C / mm to 250 C then hold for 4 min, t1(4) = 7.15 min, tr(rac-5) = 6.72 min.
Example 4: Preparation of Acetic Acid racemic trans-2-pent-4-ynyl-cyclopropyl ester (rac-Compound 6) OH AcCI, NEt3 0 Me A
MTBE
rac-5 rac-6 To a 5L flask equipped with a nitrogen inlet, mechanical stirrer, dropping funnel and thermocouple under N2 was added 31.2 g of rac-5 (251 mmol, 1.0 equiv), 350 mL of MTBE
and 45.5 mL of triethylamine (327 mmol, 1.3 equiv) prior to cooling the solution in an acetone/ice bath to an internal temp of < 5 C. To the solution was added from the dropping funnel 23.7 mL acetyl chloride (301 mmol, 1.1 equiv) over a 30 min period while maintaining the internal temp <10 C. The resulting slurry was then warmed to room temperature and aged for 2 hours. The reaction mixture was then diluted with 200 mL of water. The organic layer was washed with 200 mL of 2 N HC1 and then with 300 mL of sat. NaHCO3 prior to drying over MgSO4. The solvent was removed in vacuo to give 41.8 g of rac-6. 1HNMR (400 MHz, CDC13) 8 3.84 (dt, 111, J = 6.7, 2.9 Hz), 2.25 (dt, 2H, J= 2.7, 7.0 Hz), 2.03 (s, 3H), 1.95 (t, 1H, J= 2.6 Novozym 435 0 0.1M pH 7 buffer 0 OH +
MTBE, 10 C
rac-6 ent-5 ent-6 To a 1-L flask equipped with an overhead stirrer and temperature probe was added a 60 wt% solution of rac-6 in MTBE (44.8 g, 0.27 mol) and an additional 730 ml of MTBE that had been saturated with aqueous 0.1 M pH 7 phosphate buffer, giving a final solution temperature of approximately 10 C throughout the hydrolysis reaction, which was initiated by the addition of 730 mg Novozym 435. The reaction was aged at 10 C for approximately 4 hours until conversion had reached 41%, at which point the ee of ent-5 was 96%. The reaction mixture was then filtered through a 150-ml medium-pore glass filter funnel and the solid immobilized solvent switched to heptane. The mixture in heptane (39.2 kg, approximately 50 L) was applied to a Biotage Flash 400 L cartridge (40 x 60 cm, 40 kg silica gel, 60 angstrom, 40-63 um) and eluted sequentially with 165 L of 2.5:97.5, 75 L of 10:90, and 330 L of 25:75 Et0Ac/heptane (v/v). After the mixture was applied to the column, 18 L fractions were taken.
The rich cut analyzed by GC (HP-1, 30 m x 320 um x 0.25 urn film, 9.14 psi constant He pressure, 15:1 split, 50 C for 5 min then 25 deg/min to 275 C and hold 5 min, RT of alcohol 8.8 min). Fractions 15-21 were concentrated to give 3.48 kg (80 wt%, 92 %ee) of the desired ent-5 (Compound 7).
GC: Restek RT-Bdex SA (30 m x 0.25mm x 0.25 pm), 60 cm/s linear velocity, Example 6: Preparation of (S)-3,3-Dimethy1-24(1R,2R)-2-pent-4-ynyl-cyclopropoxycarbonylamino)-butyric acid (Compound 8) OH
1. CDI, Hunigs Base OAN CO2H
H
2.
To a 50L round bottom flask equipped with a mechanical stirrer, thermocouple and reflux condenser was added Compound 7 (3.477 kg @ 81 wt% by NMR, 92 % ee) and 14.1 L (5 L/kg) of Hunigs base. To the resulting homogeneous solution was added CDI
portion wise as a solid while maintaining the internal temperature between 21-25 C. The resulting slurry was aged at room temperature for 1 hour. To the slurry was added L-tert-leucine as a solid and the reaction mixture was heated to an internal temperature of 95 C for 2.5 hours.
The reaction mixture was cooled to room temperature and diluted with 17 L of water. The mixture was aged for 30 min to dissolve all the solids and then transferred to a 100 L
cylindrical extractor. The aqueous layer was then washed with 12 L of MTBE. The aqueous layer was washed with 8 L of MTBE. The resulting aqueous layer was pH adjusted with concentrated HCl to a final pH of 1.5-2Ø The biphasic mixture was extracted with MTBE (2 X 12 L) and the combined organic phase was washed with 6 L of water followed by 5 L of brine.
The MTBE layer was then transferred via vacuum into a 50 L round bottom flask equipped with a mechanical stirrer, thermocouple, and batch concentrator and the solvent was removed under reduced pressure keeping the internal temperature of the batch <20 C during the distillation. The solvent was then switched to cyclopentyl methyl ether (CPME) by flushing with ¨ 5 L of CPME and then diluted to a final volume of ¨ 20 L. This material was used in the next reaction without further purification.
An analytical sample was obtained by silica gel chromatography as a colorless oil: II-1 NMR (CDC13, 400 MHz) 60.54 (q, 11-1, J= 6.4 Hz), 0.83 (m, 1H), 0.99 (m, 111), 1.01 (s, 9H), 1.40 (m, 2H), 1.67 (m, 2H), 1.94 (t. 1H, J= 2.6 Hz), 2.23 (m, 2H), 3.77 (br m, 111), 4.20 (br m, 1I-1), 5.28 (br m, 1H), 9.40 (br s, 1H); I3C NMR (CDC13, 100 MHz) 6 11.8, 18.0, 26.5, 27.4, 30.1, 34.6, 55.0, 62.0, 68.4, 84.2, 156.7, 175.8.
Example 7: Preparation of 6-Methoxy-quinoxaline-2,3-diol (Compound 10) _--O 40 NH2 0 0 3N HCI
_____________________________________________________________ 0 NOH
HO, _____________________________ OH
HCI HCI
In a 50 L flask equipped with a mechanical stirrer, thermocouple and condenser was added 4-methoxy-1,2-phenylenediamine dihydrochloride salt (Compound 9) (2.65 kg @ 98 wt%, 12.30 mol), oxalic acid (1.582 kg @ 98 wt.%, 17.22 mol) and 3 N HC1 (aq) (17.8 L) under nitrogen. The grey heterogeneous slurry was heated to 90 C with steam for 7.25 hours. The reaction was monitored by HPLC. The resulting grey slurry was then cooled to an internal temperature of 20 C overnight. The slurry was filtered, water (1.0-1.5 L/Kg) was used to help with the transfer. The light grey solids were washed with 2 cake volumes water (5.0-5.5 L/Kg).
The solids were dried under vacuum/N2 sweep for 24 hours, at which time the solids were still very wet. The product was then slurry washed with methanol, and dried over 48 hours at 40-45 C in a vacuum oven to give Compound 10 as an off-white product of 99.95%
purity by HPLC
assay. There was no methanol by NMR and the KF= 0.05 wt. % water.
HPLC Conditions: Zorbax Eclipse Plus C18 50 x 4.6 mm, 1.8 urn, 1.5 mL/min, 210 nm, 25 C, Eluents: Water 0.1% H3PO4 (A), Acetonitrile (B). 90% A 0 min, 5% A 5 5% A 6 min Compound 9 (diamine HC1 salt) 0.394 min Compound 10 1.55 mm (sometimes two peaks) Example 8: Preparation of 2,3-Dichloro-6-methoxyquinoxaline (Compound 11) C) INI,OH POCI3 .õ0 NCI
____________________________________________ =
N OH N CI
In a 22 L round bottomed flask equipped with a mechanical stirrer, thermocouple and condenser was added to 2,3-dichloro-6-methoxyquinoxalone Compound 10 (3.8 kg).
Charged slowly at room temperature was POCI3 (5.92 L @ 99%). The grey slurry was heated to 98 C for 20 hours. After 2-3 hours the slurry turned from grey to green, then to yellow and finally turned homogeneous red. As the slurry became homogenous in POC13, significant amounts of HC1 off-gassing were produced. The dark red, homogenous solution was allowed to cool slowly to below 80 C. At this point, 19 L of acetonitrile (5.0 L/Kg) was charged which produced a dark brown slurry. The reaction was cooled to 10-15 C in an ice bath and reverse quenched into 45.6 L of cold water (12.0 L/Kg) in a 100 L cylindrical vessel.
This exothermic quench was kept below 27 C. MeCN (¨ 4L) was used to aide in slurry transfer.
The brown slurry was filtered and 5 L of water was used to wash the flask. The solids were washed with 1 cake volume of water (-5 L). The pH of the filtrate was acidic. The solids were next displacement washed with 2 cake volumes of 5% sodium bicarbonate (-20.00 L).
The pH was between 8-9. A slurry wash was performed with 2 cake volumes of water (20 L
total). The pH
did not change. The solids were dried for 72 hours under reduced pressure and nitrogen flow to give tan product Compound 11 of 99.5% purity by HPLC assay with KF= 0.5 wt. %
water.
HPLC Conditions: Zorbax Eclipse Plus C18 50 x 4.6 mm, 1.8 um, 1.5 mL/min, 210 nm, 25 C; Eluents: Water 0.1% H3PO4 (A), Acetonitrile (B). 90% A 0 min, 5% A 5 min, 5% A 6 min.
Compound 10 1.55 min (sometimes two peaks) Compound 11 4.55 min An analytical sample was obtained by silica gel chromatography and as a colorless foam: IHNMR (CDC13, 400 MHz) 8 0.50 (q, 1H, J = 6.3 Hz), 1.04 (br s, 11 H), 1.20 (br s, 3H), 1.45 (br s, 13 H), 1.72 (m, 2H), 2.40 (m, 1H), 2.63 (m, 1H), 2.93 9m, 2H), 3.68-3.94 (m, 9H), 4.15 (br m, 1H), 4.46 and 4.60 (t, due to rotamers, 1H, J= 7.8 Hz), 5.27 (br m, 1H), 5.78 (br m, 1H), 7.18 (m, 1H), 7.20 (m, 1H), 7.85 (m, 1H); 13C NMR (CDC13, 100 MHz) 8 11.9, 18.5, 26.6, 27.0, 28.1, 28.3, 28.4, 29.1, 30.9, 32.9, 34.1, 35.7, 36.6, 49.4, 52.1, 52.2, 52.4, 55.1, 55.7, 57.7, 58.2, 62.3, 73.5, 74.1, 80.7, 106.0, 118.8, 128.5, 133.7, 141.1, 148.2, 153.9, 154.5, 155.3, 157.1, 160.4, 173.2, 173.3, 174.4.
Example 9: Preparation of (2S,4R)-4-(3-chloro-7-methoxyquinoxalin-2-yloxy)-2-(methoxycarbonyl)pyrrolidinium methanesulfonate (14) OMe OH Me0 Me0 ______________________________________________ 0 N + DBU Me0 N 0 (t Ms0H. Me0 i Boc' N-Boc CI 0 OMe N CI NCl MeS03-To a slurry of 2,3-dichloroquinoxaline 1 1 (100 g, 0.437 mol) and N-Boc-4-trans-hydroxy-L-proline methyl ester (12, 118 g, 0.48 mol) in DMAc (500 ml, KF <
150) at ambient temperature was added DBU (86 g, 0.568 mol). The slurry was agitated at 40-45 C for ¨35 hours. The batch was then cooled to 15 C. Ethyl acetate (1.2 L) followed by citric acid (10%, 504 mL, 162 mmol) was added while the internal temperature was maintained <25 C. The organic phase was washed with a solution of 10% citric acid (200 mL) and water (200 mL) followed by water (400 mL x 2). The organic phase was azeotropically dried and solvent switched to MeCN at a final volume of ¨880 mL. MeS03H (36 mL, 0.555 mol) was added and the reaction mixture was aged at 40 C for ¨16 hours. To the reaction slurry was added MTBE
(1.05 L) dropwise over 2 hours at 35 C. Then, the batch was further cooled to 0-5 C and aged for 2-3 hours before filtration. The wet cake was displacement washed with 30%
MeCN in MTBE (600 mL x 2), and vacuum oven dried at 40 C to give the product 14.
NMR (400 MHz, d6-DMS0) 8 9.74 (s, br, 2 H), 7.86 (d, J = 9.2 Hz, 1 H), 7.34 (dd, J = 9.2, 2.8 Hz, 1 H), 7.26 (d, J = 2.8 Hz, 1 H), 5.77 (m 1 H), 4.69 (dd, J = 10.6, 7.6 Hz, 1 H), 3.92 (s, 3 H), 3.89 (dd, J = 13.2, 5.2 Hz, 1 H), 3.81 (s, 3 H), 3.63 (m, 1 H), 2.71 (m, 1 H), 2.60 (m, 1 H), 2.35 (s, 3 H).
13C NMR (100 MHz, d6-DMS0) 8 168.3, 161.0, 151.8, 140.4, 135.4, 133.3, 128.6, 119.8, 106.0, 75.6, 58.0, 56.0, 53.2, 50.5, 39.6, 33.9.
HPLC conditions: Hypersil Gold PFP column, 150 x 4.6 mm, 3.0 urn; Column temperature of 40 C; Flow rate of 1.8 mL/min; and Wavelength of 215 nm.
Gradient: min CH3CN 0.1% H3PO4 12.1 25 75 Retention times: min.
Dichloroquinoxaline 11 7.8 Proline quinoxaline 13 9.8 De-Boc quinoxaline 14 3.6 Example 10: Preparation of (S)-2-(((1R,2R)-2-(5-(6-methoxy-343R,5S)-5-(methoxycarbonyl)pyrrolidin-3-yloxy)quinoxalin-2-yl)pent-4-vnyl)cyclopropoxy)carbonylamino)-3,3-dimethylbutanoic acid (16) and alkyne macrocyclic ester (17) Me02C
bl+H2 CH3S03- Me02C
HNCO2- t-BuNH3+ .b1H
Me0 NO 0 0 PdCi2(PPh3)2 meoF
N,O
N CI Cul N
CO2Me HATU
_________________________________________ NH
Me0 N,x, . 0 N
To a three-neck flask were added copper(I) iodide (0.219 g, 1.152 mmol), chloroquinoxaline Ms0H salt 14 (50 g, 115 mmol), alkyne acid TBA salt 15 (49.3 g, 121 mmol), and bis(triphenylphosphine)palladium(II) dichloride (0.404 g, 0.573 mmol). The flask was vacuumed degassed with N2. Me0H (500 ml) was added and the reaction mixture was vacuum degassed again with N2. Triethylamine (32.1 ml, 230 mmol) was added. The reaction solution was aged at 35 C for 3-5 hours. The batch was then concentrated to a volume of ¨100 mL in vacuum. THF (250 mL) and Et0Ac (250 mL) were added. The reaction mixture was cooled to below 5 C. 11C1 solution (1 N, ¨180 mL) was added slowly at below 5 C until the reaction solution was pH adjusted to ¨2. NaCl aq. solution (10%, 350 mL) was added. The separated aqueous phase was back-extracted with a solution of THF (250 mL) and Et0Ac (250 mL). The combined organic phase was washed with 10% NaC1 aq. solution (500 mL). The organic phase was azeotropically concentrated in vacuum with THF at below 20 C until the KF
of the solution was less than 500 ppm. Then, the reaction solvent was switched to DMAc (650 mL) in vacuum at below 20 C.
A solution of HATU (55.1 g, 145 mmol) in DMAc (650 mL) at ambient temperature was vacuumed degassed with N2. The solution was then cooled to 0 C
and DIPEA
(58.5 mL, 335 mmol) was added dropwise at below 0-5 C. Then, the above solution of alkyne quinoxaline acid 16 (65 g assay, 112 mmol) in DMAc was added dropwsie over 10 hours, while maintaining the internal temperature at 0 C. After addition, the batch was agitated at 0 C for additional 2 hours. Et0Ac (750 mL) was added at below 5 C. A solution of 10%
NaC1 aq.
solution (400 mL), water (125 mL) and 1 N HC1 solution (100 mL) was slowly added while maintaining the batch temperature at below 5 C. The solution was then adjusted to pH = 2 with 1 N HC1 (-25 mL). The separated aqueous phase was back-extracted with Et0Ac (500 mL). The combined organic phase was washed with 10% NaC1 aq. solution (500 mL). After 10% NaC1 aq.
solution (500 mL) was added to the combined organic phase, the mixed solution was cooled to 0-5 C. 1 N NaOH aq. solution (-25 mL) was added to adjust the pH = -7. The separated organic phase was filtered through Celite and solvent switched to IPA at a final volume of 300 mL.
Acetic acid (5.0 mL) was added, and the batch was then heated up to reflux for 30 min. The slurry was cooled to 60 C and water (250 mL) was added dropwise over 1 hour.
After addition, the batch was aged for additional 30 min before slowly cooling to ambient temperature in about 2 hours. After aging at least 1 hour, the batch was filtered. The wet cake was displacement washed with 50% aq IPA (100 mL). Suction dry at ambient temperature afforded 56 g of macrocyclic alkyne ester 17.
1H NMR (400 MHz, CDC13) 6 7.80 (d, J = 9.2 Hz, 1 H), 7.17 (dd, J = 9.2, 2.8 Hz, 1 H), 7.04 (d, J = 2.8 Hz, 1 H), 5.82 (t, J = 4.2 Hz, 1 H), 5.26 (d, J = 9.9 Hz, 1 H), 4.62 (dd, J =
10.3, 7.3 Hz, 1 H), 4.51 (d, J = 11.6 Hz, 1 H), 4.40 (d, J = 9.9 Hz, 1 H), 4.03 (dd, J = 11.6, 4.4 Hz, 1 H), 3.91 (s, 3 H), 3.87 (m, 1 H), 3.73 (s, 3 H), 2.85 (dt, J = 12.1, 4.2 Hz, 1 H), 2.76 (d, J =
14.4, 7.3 Hz, 1 H), 2.49 (dt, J = 12.2, 5.4 Hz, 1 H), 2.30 (ddd, J = 14.6, 10.1, 4.2 Hz, 1 H), 1.99 (m, 1 H), 1.82 (m, 1 H), 1.74 (m, 1 H), 1.08 (s, 9 H), 0.92 (m, 2 H), 0.76 (m, 1 H), 0.47 (m, 1 H).
13C NMR (100 MHz, CDC13) 6 172.3, 171.3, 161.2, 157.4, 156.3, 140.4, 134.3, 130.2, 129.5, 119.5, 105.7, 98.9, 75.5, 75.2, 59.4, 58.1, 55.7, 55.6, 54.1, 52.3, 35.3, 35.0, 29.9, 28.0, 26.3, 18.7, 18.3, 10.3.
IPC HPLC conditions: Ascentis Express C18 column, 100 x 4.6 mm, 2.7micron;
Column temperature of 40 C; Flow rate of 1.8 mL/min; and Wavelength of 215 nm.
_____________________________________________________________ 0 NOH
HO, _____________________________ OH
HCI HCI
In a 50 L flask equipped with a mechanical stirrer, thermocouple and condenser was added 4-methoxy-1,2-phenylenediamine dihydrochloride salt (Compound 9) (2.65 kg @ 98 wt%, 12.30 mol), oxalic acid (1.582 kg @ 98 wt.%, 17.22 mol) and 3 N HC1 (aq) (17.8 L) under nitrogen. The grey heterogeneous slurry was heated to 90 C with steam for 7.25 hours. The reaction was monitored by HPLC. The resulting grey slurry was then cooled to an internal temperature of 20 C overnight. The slurry was filtered, water (1.0-1.5 L/Kg) was used to help with the transfer. The light grey solids were washed with 2 cake volumes water (5.0-5.5 L/Kg).
The solids were dried under vacuum/N2 sweep for 24 hours, at which time the solids were still very wet. The product was then slurry washed with methanol, and dried over 48 hours at 40-45 C in a vacuum oven to give Compound 10 as an off-white product of 99.95%
purity by HPLC
assay. There was no methanol by NMR and the KF= 0.05 wt. % water.
HPLC Conditions: Zorbax Eclipse Plus C18 50 x 4.6 mm, 1.8 urn, 1.5 mL/min, 210 nm, 25 C, Eluents: Water 0.1% H3PO4 (A), Acetonitrile (B). 90% A 0 min, 5% A 5 5% A 6 min Compound 9 (diamine HC1 salt) 0.394 min Compound 10 1.55 mm (sometimes two peaks) Example 8: Preparation of 2,3-Dichloro-6-methoxyquinoxaline (Compound 11) C) INI,OH POCI3 .õ0 NCI
____________________________________________ =
N OH N CI
In a 22 L round bottomed flask equipped with a mechanical stirrer, thermocouple and condenser was added to 2,3-dichloro-6-methoxyquinoxalone Compound 10 (3.8 kg).
Charged slowly at room temperature was POCI3 (5.92 L @ 99%). The grey slurry was heated to 98 C for 20 hours. After 2-3 hours the slurry turned from grey to green, then to yellow and finally turned homogeneous red. As the slurry became homogenous in POC13, significant amounts of HC1 off-gassing were produced. The dark red, homogenous solution was allowed to cool slowly to below 80 C. At this point, 19 L of acetonitrile (5.0 L/Kg) was charged which produced a dark brown slurry. The reaction was cooled to 10-15 C in an ice bath and reverse quenched into 45.6 L of cold water (12.0 L/Kg) in a 100 L cylindrical vessel.
This exothermic quench was kept below 27 C. MeCN (¨ 4L) was used to aide in slurry transfer.
The brown slurry was filtered and 5 L of water was used to wash the flask. The solids were washed with 1 cake volume of water (-5 L). The pH of the filtrate was acidic. The solids were next displacement washed with 2 cake volumes of 5% sodium bicarbonate (-20.00 L).
The pH was between 8-9. A slurry wash was performed with 2 cake volumes of water (20 L
total). The pH
did not change. The solids were dried for 72 hours under reduced pressure and nitrogen flow to give tan product Compound 11 of 99.5% purity by HPLC assay with KF= 0.5 wt. %
water.
HPLC Conditions: Zorbax Eclipse Plus C18 50 x 4.6 mm, 1.8 um, 1.5 mL/min, 210 nm, 25 C; Eluents: Water 0.1% H3PO4 (A), Acetonitrile (B). 90% A 0 min, 5% A 5 min, 5% A 6 min.
Compound 10 1.55 min (sometimes two peaks) Compound 11 4.55 min An analytical sample was obtained by silica gel chromatography and as a colorless foam: IHNMR (CDC13, 400 MHz) 8 0.50 (q, 1H, J = 6.3 Hz), 1.04 (br s, 11 H), 1.20 (br s, 3H), 1.45 (br s, 13 H), 1.72 (m, 2H), 2.40 (m, 1H), 2.63 (m, 1H), 2.93 9m, 2H), 3.68-3.94 (m, 9H), 4.15 (br m, 1H), 4.46 and 4.60 (t, due to rotamers, 1H, J= 7.8 Hz), 5.27 (br m, 1H), 5.78 (br m, 1H), 7.18 (m, 1H), 7.20 (m, 1H), 7.85 (m, 1H); 13C NMR (CDC13, 100 MHz) 8 11.9, 18.5, 26.6, 27.0, 28.1, 28.3, 28.4, 29.1, 30.9, 32.9, 34.1, 35.7, 36.6, 49.4, 52.1, 52.2, 52.4, 55.1, 55.7, 57.7, 58.2, 62.3, 73.5, 74.1, 80.7, 106.0, 118.8, 128.5, 133.7, 141.1, 148.2, 153.9, 154.5, 155.3, 157.1, 160.4, 173.2, 173.3, 174.4.
Example 9: Preparation of (2S,4R)-4-(3-chloro-7-methoxyquinoxalin-2-yloxy)-2-(methoxycarbonyl)pyrrolidinium methanesulfonate (14) OMe OH Me0 Me0 ______________________________________________ 0 N + DBU Me0 N 0 (t Ms0H. Me0 i Boc' N-Boc CI 0 OMe N CI NCl MeS03-To a slurry of 2,3-dichloroquinoxaline 1 1 (100 g, 0.437 mol) and N-Boc-4-trans-hydroxy-L-proline methyl ester (12, 118 g, 0.48 mol) in DMAc (500 ml, KF <
150) at ambient temperature was added DBU (86 g, 0.568 mol). The slurry was agitated at 40-45 C for ¨35 hours. The batch was then cooled to 15 C. Ethyl acetate (1.2 L) followed by citric acid (10%, 504 mL, 162 mmol) was added while the internal temperature was maintained <25 C. The organic phase was washed with a solution of 10% citric acid (200 mL) and water (200 mL) followed by water (400 mL x 2). The organic phase was azeotropically dried and solvent switched to MeCN at a final volume of ¨880 mL. MeS03H (36 mL, 0.555 mol) was added and the reaction mixture was aged at 40 C for ¨16 hours. To the reaction slurry was added MTBE
(1.05 L) dropwise over 2 hours at 35 C. Then, the batch was further cooled to 0-5 C and aged for 2-3 hours before filtration. The wet cake was displacement washed with 30%
MeCN in MTBE (600 mL x 2), and vacuum oven dried at 40 C to give the product 14.
NMR (400 MHz, d6-DMS0) 8 9.74 (s, br, 2 H), 7.86 (d, J = 9.2 Hz, 1 H), 7.34 (dd, J = 9.2, 2.8 Hz, 1 H), 7.26 (d, J = 2.8 Hz, 1 H), 5.77 (m 1 H), 4.69 (dd, J = 10.6, 7.6 Hz, 1 H), 3.92 (s, 3 H), 3.89 (dd, J = 13.2, 5.2 Hz, 1 H), 3.81 (s, 3 H), 3.63 (m, 1 H), 2.71 (m, 1 H), 2.60 (m, 1 H), 2.35 (s, 3 H).
13C NMR (100 MHz, d6-DMS0) 8 168.3, 161.0, 151.8, 140.4, 135.4, 133.3, 128.6, 119.8, 106.0, 75.6, 58.0, 56.0, 53.2, 50.5, 39.6, 33.9.
HPLC conditions: Hypersil Gold PFP column, 150 x 4.6 mm, 3.0 urn; Column temperature of 40 C; Flow rate of 1.8 mL/min; and Wavelength of 215 nm.
Gradient: min CH3CN 0.1% H3PO4 12.1 25 75 Retention times: min.
Dichloroquinoxaline 11 7.8 Proline quinoxaline 13 9.8 De-Boc quinoxaline 14 3.6 Example 10: Preparation of (S)-2-(((1R,2R)-2-(5-(6-methoxy-343R,5S)-5-(methoxycarbonyl)pyrrolidin-3-yloxy)quinoxalin-2-yl)pent-4-vnyl)cyclopropoxy)carbonylamino)-3,3-dimethylbutanoic acid (16) and alkyne macrocyclic ester (17) Me02C
bl+H2 CH3S03- Me02C
HNCO2- t-BuNH3+ .b1H
Me0 NO 0 0 PdCi2(PPh3)2 meoF
N,O
N CI Cul N
CO2Me HATU
_________________________________________ NH
Me0 N,x, . 0 N
To a three-neck flask were added copper(I) iodide (0.219 g, 1.152 mmol), chloroquinoxaline Ms0H salt 14 (50 g, 115 mmol), alkyne acid TBA salt 15 (49.3 g, 121 mmol), and bis(triphenylphosphine)palladium(II) dichloride (0.404 g, 0.573 mmol). The flask was vacuumed degassed with N2. Me0H (500 ml) was added and the reaction mixture was vacuum degassed again with N2. Triethylamine (32.1 ml, 230 mmol) was added. The reaction solution was aged at 35 C for 3-5 hours. The batch was then concentrated to a volume of ¨100 mL in vacuum. THF (250 mL) and Et0Ac (250 mL) were added. The reaction mixture was cooled to below 5 C. 11C1 solution (1 N, ¨180 mL) was added slowly at below 5 C until the reaction solution was pH adjusted to ¨2. NaCl aq. solution (10%, 350 mL) was added. The separated aqueous phase was back-extracted with a solution of THF (250 mL) and Et0Ac (250 mL). The combined organic phase was washed with 10% NaC1 aq. solution (500 mL). The organic phase was azeotropically concentrated in vacuum with THF at below 20 C until the KF
of the solution was less than 500 ppm. Then, the reaction solvent was switched to DMAc (650 mL) in vacuum at below 20 C.
A solution of HATU (55.1 g, 145 mmol) in DMAc (650 mL) at ambient temperature was vacuumed degassed with N2. The solution was then cooled to 0 C
and DIPEA
(58.5 mL, 335 mmol) was added dropwise at below 0-5 C. Then, the above solution of alkyne quinoxaline acid 16 (65 g assay, 112 mmol) in DMAc was added dropwsie over 10 hours, while maintaining the internal temperature at 0 C. After addition, the batch was agitated at 0 C for additional 2 hours. Et0Ac (750 mL) was added at below 5 C. A solution of 10%
NaC1 aq.
solution (400 mL), water (125 mL) and 1 N HC1 solution (100 mL) was slowly added while maintaining the batch temperature at below 5 C. The solution was then adjusted to pH = 2 with 1 N HC1 (-25 mL). The separated aqueous phase was back-extracted with Et0Ac (500 mL). The combined organic phase was washed with 10% NaC1 aq. solution (500 mL). After 10% NaC1 aq.
solution (500 mL) was added to the combined organic phase, the mixed solution was cooled to 0-5 C. 1 N NaOH aq. solution (-25 mL) was added to adjust the pH = -7. The separated organic phase was filtered through Celite and solvent switched to IPA at a final volume of 300 mL.
Acetic acid (5.0 mL) was added, and the batch was then heated up to reflux for 30 min. The slurry was cooled to 60 C and water (250 mL) was added dropwise over 1 hour.
After addition, the batch was aged for additional 30 min before slowly cooling to ambient temperature in about 2 hours. After aging at least 1 hour, the batch was filtered. The wet cake was displacement washed with 50% aq IPA (100 mL). Suction dry at ambient temperature afforded 56 g of macrocyclic alkyne ester 17.
1H NMR (400 MHz, CDC13) 6 7.80 (d, J = 9.2 Hz, 1 H), 7.17 (dd, J = 9.2, 2.8 Hz, 1 H), 7.04 (d, J = 2.8 Hz, 1 H), 5.82 (t, J = 4.2 Hz, 1 H), 5.26 (d, J = 9.9 Hz, 1 H), 4.62 (dd, J =
10.3, 7.3 Hz, 1 H), 4.51 (d, J = 11.6 Hz, 1 H), 4.40 (d, J = 9.9 Hz, 1 H), 4.03 (dd, J = 11.6, 4.4 Hz, 1 H), 3.91 (s, 3 H), 3.87 (m, 1 H), 3.73 (s, 3 H), 2.85 (dt, J = 12.1, 4.2 Hz, 1 H), 2.76 (d, J =
14.4, 7.3 Hz, 1 H), 2.49 (dt, J = 12.2, 5.4 Hz, 1 H), 2.30 (ddd, J = 14.6, 10.1, 4.2 Hz, 1 H), 1.99 (m, 1 H), 1.82 (m, 1 H), 1.74 (m, 1 H), 1.08 (s, 9 H), 0.92 (m, 2 H), 0.76 (m, 1 H), 0.47 (m, 1 H).
13C NMR (100 MHz, CDC13) 6 172.3, 171.3, 161.2, 157.4, 156.3, 140.4, 134.3, 130.2, 129.5, 119.5, 105.7, 98.9, 75.5, 75.2, 59.4, 58.1, 55.7, 55.6, 54.1, 52.3, 35.3, 35.0, 29.9, 28.0, 26.3, 18.7, 18.3, 10.3.
IPC HPLC conditions: Ascentis Express C18 column, 100 x 4.6 mm, 2.7micron;
Column temperature of 40 C; Flow rate of 1.8 mL/min; and Wavelength of 215 nm.
Gradient: min CH3CN 0.1% H3PO4 9.1 10 90 Retention times: min.
De-Boc quinoxaline 14 2.3 Alkyne quinoxaline acid 16 3.3 Alkyne macrocyclic ester 17 5.7 Example 11: Preparation of Macro cyclic Ester 18 Me02C 0 V
NH Me02Cõ,11-) Me0 NO - 00 Me0 A mixture of alkyne macrocyclic ester 17 (10.0 g, 17.71 mmol) and 5% Pd/C
50%wet (3.5 g, 0.822 mmol) in THF (100 mL) was hydrogenated at ambient temperature under 40 psig of hydrogen for at least 10 hours. Upon reaction completion, the batch was filtered through Celite and the filtered catalyst was washed with THF (100 mL). The combined filtrate was solvent switched to IPA in vacuum at a final volume of -50 mL. The slurry was heated up to reflux for about 1 hour. The batch was then cooled to 50 C and water (30 mL) was added dropwise over 1 hour. The batch was slowly cooled to below 0 C over 2 hour and stirred at 0 C
for additional 1 hour before filtration. The wet cake was washed with a cold solution (0-5 C) of 57% IPA in water (17.5 mL). Suction dry at ambient temperature gave 8.5 g of the desired macrocyclic ester 18.
NMR (400 MHz, CDC13) 8 7.83 (d, J = 9.2 Hz, 1 H), 7.18 (dd, J = 9.2, 2.8 Hz, 1 H), 7.1 (d, J = 2.8 Hz, 1 H), 5.98 (t, = 4.0 Hz, 1 H), 5.24 (d, J = 9.9 Hz, 1 H), 4.60 (dd, J =
10.7, 7.3 Hz, 1 H), 4.46 (d, J = 11.9 Hz, 1 H), 4.40 (d, J = 10.0 Hz,1 H), 4.01 (dd, J = 11.6, 4.0 Hz, 1 H), 3.93 (s, 3 H), 3.80 (m, 1 H), 3.75 (s. 3 H), 2.90 (ddd, J = 13.7, 11.5, 4.8 Hz, 1 H), 2.79 (ddd, J - 13.7, 12.1, 4.8 Hz, 1 H), 2.69 (dd, J = 14.2, 6.5 Hz, 1 H), 2.28 (ddd, J = 14.5, 10.7, 4.3 Hz, 1 H), 1.76 (m, 2 H), 1.66 (m, 2 H), 1.52 (m, 3 H), 1.09 (s, 9 H), 0.99 (m, 1 H), 0.92 (m, 1 H), 0.67 (m, 1 H), 0.46 (m, 1 H).
13C NMR (100 MHz, CDC13) 8 172.4, 171.5, 160.4, 157.5, 155.1, 148.7, 140.1, 134.6, 129.4, 118.7, 106.1, 74.4, 59.4, 58.2, 55.8, 55.5, 54.4, 52.5, 35.7, 35.2, 34.0, 30.9, 29.5, 28.6, 28.3, 26.5, 18.9, 11.2.
IPC HPLC conditions: Ascentis Express C18 Column, 100 x 4.6 mm, 2.7micron ;
Column temperature or 40 C; Flow rate or 1.8 mL/min; and Wavelength of 215 nm.
Gradient: min CH3CN 0.1% 113PO4 9.1 10 90 Retention times: mm.
Alkyne macro cyclicester 17 5.7 cis-Alkene maerocyclic_ester (reaction intermediate) 6.0 trans-Alkene macrocycliesster (reaction intermediate) 6.1 Compound 18 6.2 Example 12: Preparation of Macrocyclic Acid (19) OMe OMe N N ISP
I N I ,N
NaOH
OMe then, HCI k N 1:1/2 H20 re" N
To a slurry of macrocyclic ester 18 (90 g, 158.3 mmol) in Me0H (720 mL) at ambient temperature was added 2 M NaOH (237.4 mL, 475 mmol) dropwise. The reaction mixture was aged at 50 C for 2-3 hours. The reaction solution was cooled to 35-40 C and 5 N
HC1 in 50% aq Me0H (70 mL) was added dropwise. The batch was seeded with free acid hemihydrate 19 (-100 mg) and aged for 30 mm to 1 hour at 40 C. Additional 5 N
HC1 in 50%
aq Me0H (30 mL) was added dropwise over 2-4 hours at 40 C. The slurry was aged additional 1 hour before cooling to ambient temperature. The slurry was aged for additional 1 hour before filtration. The wet cake was washed with 65% Me0H in water (3x 270 mL, displacement wash, slurry wash and displacement wash). Suction dry at ambient temperature or vacuum oven dry with dry N2 sweep at 60-80 C gave 85.6 g of macrocyclic acid hemihydrate 19 as an off-white solid.
NMR (400 MHz, CDC13) 6 7.85 (d, J = 9.0 Hz, 1 H), 7.19 (dd, J = 9.0, 2.8 Hz, 1 H), 7.13 (d, J = 2.8 Hz, 1 H), 5.99 (t, J = 3.9 Hz, 1 H), 5.45 (d, J = 9.9 Hz, 1 H), 4.80 (s, br, 2 H, COOH, hemihydrate H20), 4.64 (dd, J = 10.4, 7.4 Hz, 1 H), 4.49 (d, J = 11.6 Hz, 1 H), 4.44 (d, J = 10.0 Hz, 1 H), 3.99 (dd, J = 11.7, 4.0 Hz, 1 H), 3.94 (s, 3 H), 3.81 (m, 1 H), 2.90 (ddd, J =
13.8, 11.8, 4.8, 1 H), 2.80 (ddd, J = 13.8, 11.8, 4.8 Hz, 1 1-1), 2.71 (dd, J
= 14.3, 7.3, 1 H), 2.42 (ddd, J = 14.4, 10.6, 4.2 Hz, 1 H), 1.76 (m, 2 H), 1.66 (m, 2 H), 1.52 (m, 3 H), 1.07 (s, 9 H), 0.96 (m, 2 H), 0.67 (m, 1 H), 0.47 (m, 1 H).
13C NMR (100 MHz, CDC13) 6 174.5, 172.1, 160.5, 157.6, 155.1, 148.6, 141.0, 134.3, 129.1, 118.9, 106.1, 74.3, 59.6, 58.3, 55.6, 54.6, 35.6, 35.3, 33.7, 30.8, 29.4, 28.6, 28.3, 26.5, 18.9, 11.2.
IPC HPLC conditions: Hypersil Gold PFP Column, 150 x 4.6mm, 3.0um, Column temperature of 40 C; Flow rate of 1.8 mL/min; and Wavelength of 215 nm Gradient: min CH3CN 0.1% H3PO4 12.1 25 75 Retention times: mm.
Compound 18 6.78 Compound 19 5.41 Example 13: Preparation of Compound A
OMe O OMe N
N I .N
I .N
Ts0- 0 R
H3N+
EDC, Py, THF-DMAc .00 cs( N H 0 0, ,0 N,<:J(t,ri:Sv Compound A hydrate Macrocyclic acid hemihydrate 19 (10.16 g, 18.03 mmol) was dissolved in THF
De-Boc quinoxaline 14 2.3 Alkyne quinoxaline acid 16 3.3 Alkyne macrocyclic ester 17 5.7 Example 11: Preparation of Macro cyclic Ester 18 Me02C 0 V
NH Me02Cõ,11-) Me0 NO - 00 Me0 A mixture of alkyne macrocyclic ester 17 (10.0 g, 17.71 mmol) and 5% Pd/C
50%wet (3.5 g, 0.822 mmol) in THF (100 mL) was hydrogenated at ambient temperature under 40 psig of hydrogen for at least 10 hours. Upon reaction completion, the batch was filtered through Celite and the filtered catalyst was washed with THF (100 mL). The combined filtrate was solvent switched to IPA in vacuum at a final volume of -50 mL. The slurry was heated up to reflux for about 1 hour. The batch was then cooled to 50 C and water (30 mL) was added dropwise over 1 hour. The batch was slowly cooled to below 0 C over 2 hour and stirred at 0 C
for additional 1 hour before filtration. The wet cake was washed with a cold solution (0-5 C) of 57% IPA in water (17.5 mL). Suction dry at ambient temperature gave 8.5 g of the desired macrocyclic ester 18.
NMR (400 MHz, CDC13) 8 7.83 (d, J = 9.2 Hz, 1 H), 7.18 (dd, J = 9.2, 2.8 Hz, 1 H), 7.1 (d, J = 2.8 Hz, 1 H), 5.98 (t, = 4.0 Hz, 1 H), 5.24 (d, J = 9.9 Hz, 1 H), 4.60 (dd, J =
10.7, 7.3 Hz, 1 H), 4.46 (d, J = 11.9 Hz, 1 H), 4.40 (d, J = 10.0 Hz,1 H), 4.01 (dd, J = 11.6, 4.0 Hz, 1 H), 3.93 (s, 3 H), 3.80 (m, 1 H), 3.75 (s. 3 H), 2.90 (ddd, J = 13.7, 11.5, 4.8 Hz, 1 H), 2.79 (ddd, J - 13.7, 12.1, 4.8 Hz, 1 H), 2.69 (dd, J = 14.2, 6.5 Hz, 1 H), 2.28 (ddd, J = 14.5, 10.7, 4.3 Hz, 1 H), 1.76 (m, 2 H), 1.66 (m, 2 H), 1.52 (m, 3 H), 1.09 (s, 9 H), 0.99 (m, 1 H), 0.92 (m, 1 H), 0.67 (m, 1 H), 0.46 (m, 1 H).
13C NMR (100 MHz, CDC13) 8 172.4, 171.5, 160.4, 157.5, 155.1, 148.7, 140.1, 134.6, 129.4, 118.7, 106.1, 74.4, 59.4, 58.2, 55.8, 55.5, 54.4, 52.5, 35.7, 35.2, 34.0, 30.9, 29.5, 28.6, 28.3, 26.5, 18.9, 11.2.
IPC HPLC conditions: Ascentis Express C18 Column, 100 x 4.6 mm, 2.7micron ;
Column temperature or 40 C; Flow rate or 1.8 mL/min; and Wavelength of 215 nm.
Gradient: min CH3CN 0.1% 113PO4 9.1 10 90 Retention times: mm.
Alkyne macro cyclicester 17 5.7 cis-Alkene maerocyclic_ester (reaction intermediate) 6.0 trans-Alkene macrocycliesster (reaction intermediate) 6.1 Compound 18 6.2 Example 12: Preparation of Macrocyclic Acid (19) OMe OMe N N ISP
I N I ,N
NaOH
OMe then, HCI k N 1:1/2 H20 re" N
To a slurry of macrocyclic ester 18 (90 g, 158.3 mmol) in Me0H (720 mL) at ambient temperature was added 2 M NaOH (237.4 mL, 475 mmol) dropwise. The reaction mixture was aged at 50 C for 2-3 hours. The reaction solution was cooled to 35-40 C and 5 N
HC1 in 50% aq Me0H (70 mL) was added dropwise. The batch was seeded with free acid hemihydrate 19 (-100 mg) and aged for 30 mm to 1 hour at 40 C. Additional 5 N
HC1 in 50%
aq Me0H (30 mL) was added dropwise over 2-4 hours at 40 C. The slurry was aged additional 1 hour before cooling to ambient temperature. The slurry was aged for additional 1 hour before filtration. The wet cake was washed with 65% Me0H in water (3x 270 mL, displacement wash, slurry wash and displacement wash). Suction dry at ambient temperature or vacuum oven dry with dry N2 sweep at 60-80 C gave 85.6 g of macrocyclic acid hemihydrate 19 as an off-white solid.
NMR (400 MHz, CDC13) 6 7.85 (d, J = 9.0 Hz, 1 H), 7.19 (dd, J = 9.0, 2.8 Hz, 1 H), 7.13 (d, J = 2.8 Hz, 1 H), 5.99 (t, J = 3.9 Hz, 1 H), 5.45 (d, J = 9.9 Hz, 1 H), 4.80 (s, br, 2 H, COOH, hemihydrate H20), 4.64 (dd, J = 10.4, 7.4 Hz, 1 H), 4.49 (d, J = 11.6 Hz, 1 H), 4.44 (d, J = 10.0 Hz, 1 H), 3.99 (dd, J = 11.7, 4.0 Hz, 1 H), 3.94 (s, 3 H), 3.81 (m, 1 H), 2.90 (ddd, J =
13.8, 11.8, 4.8, 1 H), 2.80 (ddd, J = 13.8, 11.8, 4.8 Hz, 1 1-1), 2.71 (dd, J
= 14.3, 7.3, 1 H), 2.42 (ddd, J = 14.4, 10.6, 4.2 Hz, 1 H), 1.76 (m, 2 H), 1.66 (m, 2 H), 1.52 (m, 3 H), 1.07 (s, 9 H), 0.96 (m, 2 H), 0.67 (m, 1 H), 0.47 (m, 1 H).
13C NMR (100 MHz, CDC13) 6 174.5, 172.1, 160.5, 157.6, 155.1, 148.6, 141.0, 134.3, 129.1, 118.9, 106.1, 74.3, 59.6, 58.3, 55.6, 54.6, 35.6, 35.3, 33.7, 30.8, 29.4, 28.6, 28.3, 26.5, 18.9, 11.2.
IPC HPLC conditions: Hypersil Gold PFP Column, 150 x 4.6mm, 3.0um, Column temperature of 40 C; Flow rate of 1.8 mL/min; and Wavelength of 215 nm Gradient: min CH3CN 0.1% H3PO4 12.1 25 75 Retention times: mm.
Compound 18 6.78 Compound 19 5.41 Example 13: Preparation of Compound A
OMe O OMe N
N I .N
I .N
Ts0- 0 R
H3N+
EDC, Py, THF-DMAc .00 cs( N H 0 0, ,0 N,<:J(t,ri:Sv Compound A hydrate Macrocyclic acid hemihydrate 19 (10.16 g, 18.03 mmol) was dissolved in THF
(50 - 90 mL). The solution was azetropically dried at a final volume of 100 mL. Sulfonamide pTSA salt 20 (7.98 g, 1.983 mmol) followed by DMAc (15 mL) was added at ambient temperature. The batch was cooled to 0-10 C and pyridine (10 mL) was added dropwise. Then, EDC HC1 (4.49 g, 23.44 mmol) was added in portions or one portion at 0-10 C.
The reaction mixture was aged at 0-10 C for 1 hour, then warmed to 15-20 C for 2-4 hours.
Me0Ac (100 mL) followed by 15wt% citirc acid in 5% NaC1 in water (50 mL) was added, while the internal temperature was maintained to <25 C with external cooling. The separated organic phase was washed with 15wt% citirc acid in 5% NaCl in water (50 mL) followed by 5% NaC1 (50 mL). The organic phase was solvent switched to acetone at a final volume of -80 mL.
Water (10 mL) was added dropwise at 35-40 C. The batch was seeded with Compound A monohydrate form III
(-10 mg) and aged for 0.5 -1 hour at 35-40 C. Additional water (22 mL) was added dropwise over 2-4 hours at 35-40 C. The slurry was aged at 20 C for 2-4 hours before filtration. The wet cake was displacement washed with 60% acetone in water (40 mL x 2). Suction dry at ambient temperature gave Compound A monohydrate form III as a white solid.
NMR (400 MHz, CDC13) 8 9.95 (s, br, 1 H), 7.81 (d, J = 9.1 Hz, 1 H), 7.18 (dd, J = 9.1, 2.7 Hz, 1 H), 7.16 (s, br, 1 H), 7.13 (d, J = 2.7 Hz, 1 H), 5.96 (t, J = 3.8 Hz, 1 H), 5.72 (m, 1 H), 5.68 (d, J = 10.1 Hz, 1 H), 5.19 (d, J = 17.1 Hz, 1 H), 5.07 (d, J = 10.1 Hz, 1 H), 4.52 (d, J = 11.4 Hz, 1 H), 4.45 (d, J = 9.8 Hz, 1 H), 4.36 (d, J = 10.5, 6.9 Hz, 1 H), 4.05 (dd, J =
11.5, 3.9 Hz, 1 H), 3.93 (s, 3 H), 3.78 (m, 1 H), 2.90 (in, 1 H), 2.82 (tt, J
= 8.0, 4.8 Hz, 1 H), 2.74 (dt, J = 13.2, 4.8 Hz, 1 H), 2.59 (dd, J = 14.0, 6.7 Hz, 1 H), 2.40 (ddd, J =
14.0, 10.6, 4.0 Hz, 1 H), 2.10 (dd, J = 17.7, 8.7 Hz, 1 H), 1.98(2 H, mono hydrate 1120), 1.88 (dd, J 8.2, 5.9 Hz, 1 HO, 1.74 (m, 3 H), 1.61 (m, 1 H), 1.50 (m, 3 H), 1.42 (dd, J = 9.6, 5.8 Hz, 1 H), 1.22 (m, 2 H), 1.07 (s, 9 H), 0.95 (m, 4 H), 0.69 (m, 1 H), 0.47 (m, 1 H).
13C NMR (100 MHz, CDC13) 8 173.5, 172.1, 169.1, 160.4, 157.7, 154.9, 148.4, 141.0, 134.3, 132.7, 129.1, 118.8, 118.7, 106.5, 74.4, 59.6, 59.4, 55.8, 55.5, 54.9, 41.8, 35.4, 35.3, 35.2, 34.3,. 31.2, 30.7, 29.5, 28.6, 28.2, 26.6, 22.6, 18.7, 11.2, 6.31, 6.17.
HPLC conditions: Ascentis Express Column, 10 cm x 4.6mm x 2.7vim; Column temperature of 40 C; Flow rate of 1.8 mL/min; and Wavelength of 215 nm Gradient: min CH3CN 0.1% H3 PO4 27.1 20 80 Retention times: min.
Compound A 14.50 Example 14: Alternative Procedure for Making Compound A
H NH
H2N,9k, N ________________________________________ H V
_______________________ NH pTSA NH
Me0 Me0 N 0 ___________________________________________________ 01 T\_ 0 RT, EDC
lµr MeCN, Py 19 acetone water Compound A, hydrate form III
To a 50 L flask equipped with overhead stirring was added macrocyclic acid 19 (1.06 kg crude,1.00eq), amine-pTSA (862 g crude, 1.12q) and MeCN 7.42 L at 19 C. The slurry was cooled in a water bath, pyridine (2.12 L, 13.8eq) was added, aged 15 minutes, and then added EDC (586 g, 1.60eq) in one portion, aged 1.5 hours while it turned into a clear homogeneous solution.
The solution cooled in a water bath, then quenched with 2 N HC1 (1.7 L), seeded (9.2 g), aged 15 minutes, and the rest of the aqueous HC1 was added over 2.5 hours. A yellow slurry was formed. The slurry was aged overnight at RT, filtered, washed with MeCN/water (1:1 v/v) 8 L, to obtain Compound A (Hydrate II).
Compound A was dissolved in acetone 4 L at RT, filtered and transferred to a L RBF with overhead stirring, rinsed with extra acetone 1 L, heated to 50 C, water 0.9 L was added, seeded 10 g, aged 15 minutes, then added water 0.8 L over 2.5 hours, extra water 3.3v over 2.5 hours was added, stopped heating, cooled to RT, aged at RT overnight, filtered, washed with water/acetone (1:1v/v) 4 L, and dried in air under vacuum. Compound A
Hydrate III, 670 g, was obtained as an off-white solid.
The reaction mixture was aged at 0-10 C for 1 hour, then warmed to 15-20 C for 2-4 hours.
Me0Ac (100 mL) followed by 15wt% citirc acid in 5% NaC1 in water (50 mL) was added, while the internal temperature was maintained to <25 C with external cooling. The separated organic phase was washed with 15wt% citirc acid in 5% NaCl in water (50 mL) followed by 5% NaC1 (50 mL). The organic phase was solvent switched to acetone at a final volume of -80 mL.
Water (10 mL) was added dropwise at 35-40 C. The batch was seeded with Compound A monohydrate form III
(-10 mg) and aged for 0.5 -1 hour at 35-40 C. Additional water (22 mL) was added dropwise over 2-4 hours at 35-40 C. The slurry was aged at 20 C for 2-4 hours before filtration. The wet cake was displacement washed with 60% acetone in water (40 mL x 2). Suction dry at ambient temperature gave Compound A monohydrate form III as a white solid.
NMR (400 MHz, CDC13) 8 9.95 (s, br, 1 H), 7.81 (d, J = 9.1 Hz, 1 H), 7.18 (dd, J = 9.1, 2.7 Hz, 1 H), 7.16 (s, br, 1 H), 7.13 (d, J = 2.7 Hz, 1 H), 5.96 (t, J = 3.8 Hz, 1 H), 5.72 (m, 1 H), 5.68 (d, J = 10.1 Hz, 1 H), 5.19 (d, J = 17.1 Hz, 1 H), 5.07 (d, J = 10.1 Hz, 1 H), 4.52 (d, J = 11.4 Hz, 1 H), 4.45 (d, J = 9.8 Hz, 1 H), 4.36 (d, J = 10.5, 6.9 Hz, 1 H), 4.05 (dd, J =
11.5, 3.9 Hz, 1 H), 3.93 (s, 3 H), 3.78 (m, 1 H), 2.90 (in, 1 H), 2.82 (tt, J
= 8.0, 4.8 Hz, 1 H), 2.74 (dt, J = 13.2, 4.8 Hz, 1 H), 2.59 (dd, J = 14.0, 6.7 Hz, 1 H), 2.40 (ddd, J =
14.0, 10.6, 4.0 Hz, 1 H), 2.10 (dd, J = 17.7, 8.7 Hz, 1 H), 1.98(2 H, mono hydrate 1120), 1.88 (dd, J 8.2, 5.9 Hz, 1 HO, 1.74 (m, 3 H), 1.61 (m, 1 H), 1.50 (m, 3 H), 1.42 (dd, J = 9.6, 5.8 Hz, 1 H), 1.22 (m, 2 H), 1.07 (s, 9 H), 0.95 (m, 4 H), 0.69 (m, 1 H), 0.47 (m, 1 H).
13C NMR (100 MHz, CDC13) 8 173.5, 172.1, 169.1, 160.4, 157.7, 154.9, 148.4, 141.0, 134.3, 132.7, 129.1, 118.8, 118.7, 106.5, 74.4, 59.6, 59.4, 55.8, 55.5, 54.9, 41.8, 35.4, 35.3, 35.2, 34.3,. 31.2, 30.7, 29.5, 28.6, 28.2, 26.6, 22.6, 18.7, 11.2, 6.31, 6.17.
HPLC conditions: Ascentis Express Column, 10 cm x 4.6mm x 2.7vim; Column temperature of 40 C; Flow rate of 1.8 mL/min; and Wavelength of 215 nm Gradient: min CH3CN 0.1% H3 PO4 27.1 20 80 Retention times: min.
Compound A 14.50 Example 14: Alternative Procedure for Making Compound A
H NH
H2N,9k, N ________________________________________ H V
_______________________ NH pTSA NH
Me0 Me0 N 0 ___________________________________________________ 01 T\_ 0 RT, EDC
lµr MeCN, Py 19 acetone water Compound A, hydrate form III
To a 50 L flask equipped with overhead stirring was added macrocyclic acid 19 (1.06 kg crude,1.00eq), amine-pTSA (862 g crude, 1.12q) and MeCN 7.42 L at 19 C. The slurry was cooled in a water bath, pyridine (2.12 L, 13.8eq) was added, aged 15 minutes, and then added EDC (586 g, 1.60eq) in one portion, aged 1.5 hours while it turned into a clear homogeneous solution.
The solution cooled in a water bath, then quenched with 2 N HC1 (1.7 L), seeded (9.2 g), aged 15 minutes, and the rest of the aqueous HC1 was added over 2.5 hours. A yellow slurry was formed. The slurry was aged overnight at RT, filtered, washed with MeCN/water (1:1 v/v) 8 L, to obtain Compound A (Hydrate II).
Compound A was dissolved in acetone 4 L at RT, filtered and transferred to a L RBF with overhead stirring, rinsed with extra acetone 1 L, heated to 50 C, water 0.9 L was added, seeded 10 g, aged 15 minutes, then added water 0.8 L over 2.5 hours, extra water 3.3v over 2.5 hours was added, stopped heating, cooled to RT, aged at RT overnight, filtered, washed with water/acetone (1:1v/v) 4 L, and dried in air under vacuum. Compound A
Hydrate III, 670 g, was obtained as an off-white solid.
Example 15: Alternative Preparation of Macrocyclic Ester (18) Me02C
1.4 Qr, -H2 Me02C
HN"-0O2- t-BuNH3+
Me0 NO 0S N 0 paci2(pph3)2 meo Ati Ny Cul N
CO2Me Me02C
¨NH 0 Pd(01-1)2, H2 HN CO2H HATU
MO so N 0 NH
Me0 NT\,_ To a three-neck flask were added copper(I) iodide (0.020 g, 0.104 mmol), chloroquinoxaline Ms0H salt 14 (4.5 g, 10.5 mmol), alkyne acid TBA salt 15 (4.4 g, 10.9 mmol), and bis(triphenylphosphine)palladium(H) dichloride (0.036 g, 0.052 mmol). The flask was vacuumed degassed with N2. Me0H (45 ml) was added and the reaction mixture was vacuum degassed again with N2. Triethylamine (2.89 ml, 20.7 mmol) was added. The reaction solution was aged at 35 C for 3-5 hours. The batch was then concentrated to a volume of ¨9 mL in vacuum. THF (23 mL) and Et0Ac (23 mL) were added. The reaction mixture was cooled to below 5 C. HC1 solution (1 N, ¨16 mL) was added slowly at below 5 C until the reaction solution was pH adjusted to ¨2. NaC1 aq. solution (10%, 32 mL) was added. The separated aqueous phase was back-extracted with a solution of THF (23 mL) and Et0Ac (23 mL). The combined organic phase was washed with 10% NaCl aq. solution (45 mL). The solvent was switched to Me0H (75 mL) in vacuum at below 20 C.
To the reaction mixture was added DARCO KB-B (1.0 g), and the resulting suspension was stirred at 20 C for 1 hour followed by filtration through Celite. The wet cake was washed with Me0H (25 mL). The combined filtrate was hydrogenated in the presence of Pearlman's catalyst (1.2 g, 20% Pd(OH)2 on carbon, 50% wet) under 1 atmosphere of hydrogen at ambient temperature for at least 5 hours. Upon reaction completion, the suspension was filtered through Celite and the filtrate containing acid 21 was solvent switched to DMAc (65 mL).
A solution of HATU (5.05 g, 13.3 mmol) in DMAc (65 mL) at ambient temperature was vacuumed degassed with N2. The solution was cooled to 0 C and DIPEA (5.4 mL, 30.9 mmol) was added dropwise at 0-5 C. Then, the above solution of acid 21(5.98 g assay, 10.2 mmol) in DMAc was added dropwsie over 10 hours, while maintaining the internal temperature at 0 C. After addition, the batch was agitated at 0 C for additional 2 hours to afford macrocyclic ester 18. The workup procedure and isolation of macrocyclic ester 18 were the same as described in Example 11.
Example 16: Compound 19 Characterization Compound 19 was characterized using different techniques, including X-ray diffraction and solid-state carbon-13 nuclear magnetic resonance (NMR) spectra. The X-ray powder diffraction patterns were generated on a Philips Analytical X'Pert PRO
X-ray Diffraction System with PW3040/60 console. A PW3373/00 ceramic Cu LEF X-ray tube K-Alpha radiation was used as the source.
The carbon-13 spectra were recorded using a Bruker 4 mm HXY triple resonance CPMAS, and a Bruker 4 mm H/FX double resonance CPMAS probe, respectively. The carbon-13 spectra were collected utilizing proton/carbon-13 variable-amplitude cross-polarization (VACP) with a contact time of 3 ins, and a pulse delay of 3 s, while magic-angle spinning (MAS) the samples at 13 kHz. A line broadening of 30 Hz was applied to the carbon-13 spectra before Fourier Transformation. Chemical shifts are reported on the TMS scale using the carbonyl carbon of glycine (176.7 ppm) as a secondary reference.
Figure 1 provides a characteristic X-ray diffraction pattern of the crystalline Compound 19 hydrate I. The hydrate exhibited characteristic reflections corresponding to d-spacings of:
Table 7 Height Pos. [ 2Th.] [cts] d-spacing [A]
8.7 723.1 10.2 22.2 277.9 4.0 23.5 216.8 3.8 8.3 214.3 10.7 14.7 199.8 6.0 7.6 178.7 11.7 22.8 101.6 3.9 11.3 87.9 7.9 Figure 2 shows the solid state carbon-13 CPMAS NMR spectrum for the Compound 19 hydrate 1. Characteristic peaks for hydrate I are observed at 174.7, 172.0, 161.4, 156.8, 156.3, 149.5, 142.1, 133.9, 128.2, 121.3, 105.0, 76.9, 60.7, 57.5, 55.1, 53.5, 35.8, 34.7, 33.4, 32.4, 29.5, 27.8, 24.0, and 20.2 ppm.
Example 18: Compound 14 Methylsulfonic acid, MeCN Solvate Characterization The MeCN solvate of compound 18 methylsulfonic acid salt, was characterized by X-ray diffraction. The results are shown in Figure 3. Characteristic peaks are provided in Table 8.
The X-ray powder diffraction patterns were generated on a Philips Analytical X'Pert PRO X-ray Diffraction System with PW3040/60 console. A PW3373/00 ceramic Cu LEF
X-ray tube K-Alpha radiation was used as the source.
Table 8 d- Rel.
spacing Pos. Height Int.
[A] [ 2Th.] [cts] [%]
16.8 5.3 660.4 100.0 7.4 12.0 476.3 72.1 6.3 14.1 240.5 36.4 3.9 22.7 176.9 26.8 9.5 9.3 168.8 25.6 5.5 16.1 134.4 20.3 4.2 20.9 105.0 15.9 5.2 17.2 77.1 11.7 3.4 25.8 29.0 4.4 2.8 32.3 25.4 3.9 None of the references described throughout the present application are admitted to be prior art to the claimed invention.
1.4 Qr, -H2 Me02C
HN"-0O2- t-BuNH3+
Me0 NO 0S N 0 paci2(pph3)2 meo Ati Ny Cul N
CO2Me Me02C
¨NH 0 Pd(01-1)2, H2 HN CO2H HATU
MO so N 0 NH
Me0 NT\,_ To a three-neck flask were added copper(I) iodide (0.020 g, 0.104 mmol), chloroquinoxaline Ms0H salt 14 (4.5 g, 10.5 mmol), alkyne acid TBA salt 15 (4.4 g, 10.9 mmol), and bis(triphenylphosphine)palladium(H) dichloride (0.036 g, 0.052 mmol). The flask was vacuumed degassed with N2. Me0H (45 ml) was added and the reaction mixture was vacuum degassed again with N2. Triethylamine (2.89 ml, 20.7 mmol) was added. The reaction solution was aged at 35 C for 3-5 hours. The batch was then concentrated to a volume of ¨9 mL in vacuum. THF (23 mL) and Et0Ac (23 mL) were added. The reaction mixture was cooled to below 5 C. HC1 solution (1 N, ¨16 mL) was added slowly at below 5 C until the reaction solution was pH adjusted to ¨2. NaC1 aq. solution (10%, 32 mL) was added. The separated aqueous phase was back-extracted with a solution of THF (23 mL) and Et0Ac (23 mL). The combined organic phase was washed with 10% NaCl aq. solution (45 mL). The solvent was switched to Me0H (75 mL) in vacuum at below 20 C.
To the reaction mixture was added DARCO KB-B (1.0 g), and the resulting suspension was stirred at 20 C for 1 hour followed by filtration through Celite. The wet cake was washed with Me0H (25 mL). The combined filtrate was hydrogenated in the presence of Pearlman's catalyst (1.2 g, 20% Pd(OH)2 on carbon, 50% wet) under 1 atmosphere of hydrogen at ambient temperature for at least 5 hours. Upon reaction completion, the suspension was filtered through Celite and the filtrate containing acid 21 was solvent switched to DMAc (65 mL).
A solution of HATU (5.05 g, 13.3 mmol) in DMAc (65 mL) at ambient temperature was vacuumed degassed with N2. The solution was cooled to 0 C and DIPEA (5.4 mL, 30.9 mmol) was added dropwise at 0-5 C. Then, the above solution of acid 21(5.98 g assay, 10.2 mmol) in DMAc was added dropwsie over 10 hours, while maintaining the internal temperature at 0 C. After addition, the batch was agitated at 0 C for additional 2 hours to afford macrocyclic ester 18. The workup procedure and isolation of macrocyclic ester 18 were the same as described in Example 11.
Example 16: Compound 19 Characterization Compound 19 was characterized using different techniques, including X-ray diffraction and solid-state carbon-13 nuclear magnetic resonance (NMR) spectra. The X-ray powder diffraction patterns were generated on a Philips Analytical X'Pert PRO
X-ray Diffraction System with PW3040/60 console. A PW3373/00 ceramic Cu LEF X-ray tube K-Alpha radiation was used as the source.
The carbon-13 spectra were recorded using a Bruker 4 mm HXY triple resonance CPMAS, and a Bruker 4 mm H/FX double resonance CPMAS probe, respectively. The carbon-13 spectra were collected utilizing proton/carbon-13 variable-amplitude cross-polarization (VACP) with a contact time of 3 ins, and a pulse delay of 3 s, while magic-angle spinning (MAS) the samples at 13 kHz. A line broadening of 30 Hz was applied to the carbon-13 spectra before Fourier Transformation. Chemical shifts are reported on the TMS scale using the carbonyl carbon of glycine (176.7 ppm) as a secondary reference.
Figure 1 provides a characteristic X-ray diffraction pattern of the crystalline Compound 19 hydrate I. The hydrate exhibited characteristic reflections corresponding to d-spacings of:
Table 7 Height Pos. [ 2Th.] [cts] d-spacing [A]
8.7 723.1 10.2 22.2 277.9 4.0 23.5 216.8 3.8 8.3 214.3 10.7 14.7 199.8 6.0 7.6 178.7 11.7 22.8 101.6 3.9 11.3 87.9 7.9 Figure 2 shows the solid state carbon-13 CPMAS NMR spectrum for the Compound 19 hydrate 1. Characteristic peaks for hydrate I are observed at 174.7, 172.0, 161.4, 156.8, 156.3, 149.5, 142.1, 133.9, 128.2, 121.3, 105.0, 76.9, 60.7, 57.5, 55.1, 53.5, 35.8, 34.7, 33.4, 32.4, 29.5, 27.8, 24.0, and 20.2 ppm.
Example 18: Compound 14 Methylsulfonic acid, MeCN Solvate Characterization The MeCN solvate of compound 18 methylsulfonic acid salt, was characterized by X-ray diffraction. The results are shown in Figure 3. Characteristic peaks are provided in Table 8.
The X-ray powder diffraction patterns were generated on a Philips Analytical X'Pert PRO X-ray Diffraction System with PW3040/60 console. A PW3373/00 ceramic Cu LEF
X-ray tube K-Alpha radiation was used as the source.
Table 8 d- Rel.
spacing Pos. Height Int.
[A] [ 2Th.] [cts] [%]
16.8 5.3 660.4 100.0 7.4 12.0 476.3 72.1 6.3 14.1 240.5 36.4 3.9 22.7 176.9 26.8 9.5 9.3 168.8 25.6 5.5 16.1 134.4 20.3 4.2 20.9 105.0 15.9 5.2 17.2 77.1 11.7 3.4 25.8 29.0 4.4 2.8 32.3 25.4 3.9 None of the references described throughout the present application are admitted to be prior art to the claimed invention.
Claims (14)
1. A method of making Compound A or a salt thereof:
comprising the step of coupling or salt thereof, to or salt thereof, wherein the coupling comprises the use of a coupling reagent and pyridine or a pyridine derivative.
comprising the step of coupling or salt thereof, to or salt thereof, wherein the coupling comprises the use of a coupling reagent and pyridine or a pyridine derivative.
2. The method of claim 1, wherein said coupling agent is EDC, and the method comprises the use of at least 10 equivalents of pyridine and acetonitrile.
3. The method of claim 1, wherein said coupling agent is EDC, and the method comprises the use of THF-DMAc or THF and a temperature range of -10 °C
to 50 °C.
to 50 °C.
4. A compound having the structure of Formula I or a salt thereof:
wherein R1 is a leaving group, or provided that if R1 is a leaving group, then R2 is H; and if R1 is Structure I, then R2 is H and R3 is OH, or R2 and R3 are joined together as a covalent bond;
R4 either C1-6alkyl or aryl; and R5 is either a C1-8 alkyl or C3-8 cycloalkyl.
wherein R1 is a leaving group, or provided that if R1 is a leaving group, then R2 is H; and if R1 is Structure I, then R2 is H and R3 is OH, or R2 and R3 are joined together as a covalent bond;
R4 either C1-6alkyl or aryl; and R5 is either a C1-8 alkyl or C3-8 cycloalkyl.
5. The compound of claim 4, wherein said compound is selected from the group consisting of:
and or a salt thereof.
and or a salt thereof.
6. The compound of claim 5, wherein said compound is a MeCN solvate of a Compound 14 methylsulfonic acid salt, wherein said solvate is characterized by an X-ray powder diffraction pattern obtained using copper K.alpha. radiation which comprises 2.THETA. values in degrees of about 5.3, 12.0, and 14.
7. A method of making a compound of claim 4, comprising the step of:
wherein 14A, 15A, and 16A may be provided as a salt.
wherein 14A, 15A, and 16A may be provided as a salt.
8. A method of making a compound of claim 6, comprising the step of:
wherein Compounds 14, 15, and 16 may be provided as a salt.
wherein Compounds 14, 15, and 16 may be provided as a salt.
9. A method of making a compound of claim 6, comprising the steps of:
wherein Compounds 14, 15, 16, and 17 may be provided as a salt, and Compound 6 is not isolated prior to lactamization.
wherein Compounds 14, 15, 16, and 17 may be provided as a salt, and Compound 6 is not isolated prior to lactamization.
10. A method of making Compound 18 comprising the steps of:
wherein any of compounds 14, 15, 16, 21 and 18 may be provided as salts, and compounds 16 and 21 are not isolated.
wherein any of compounds 14, 15, 16, 21 and 18 may be provided as salts, and compounds 16 and 21 are not isolated.
11. The method of any of claims 8-10, wherein Compound 14 is the solvate of claim 6, and Compound 15 is a TBA salt.
12. The method of anyone of claims 8-11, further comprising the making Compound 14 by a method comprising the steps:
wherein compounds 11, 12, 13 and 14 may be provided as a salt, and Compound 13 is not isolated prior to deprotection; and PG is a protecting group.
wherein compounds 11, 12, 13 and 14 may be provided as a salt, and Compound 13 is not isolated prior to deprotection; and PG is a protecting group.
13. A compound selected from the group consisting of:
a) a MeCN solvate of a Compound 14 methylsulfonic acid salt, where the solvate is characterized by an X-ray powder diffraction pattern obtained using copper K.alpha.
radiation which comprises 2.THETA. values in degrees of about 5.3, 12.0, and
a) a MeCN solvate of a Compound 14 methylsulfonic acid salt, where the solvate is characterized by an X-ray powder diffraction pattern obtained using copper K.alpha.
radiation which comprises 2.THETA. values in degrees of about 5.3, 12.0, and
14.1; and b) Compound 19 hydrate characterized by either (i) an X-ray powder diffraction pattern obtained using copper K.alpha. radiation which comprises 2.THETA.
values in degrees of about 8.7, 22.2, and 23.5; or (ii) a solid state carbon-13 CPMAS NMR comprising peaks at about 174.7, 172.0, 161.4, 156.8, 156.3, 149.5, 142.1, 133.9, 128.2, 121.3, 105.0, 76.9, 60.7, 57.5, 55.1, 53.5, 35.8, 34.7, 33.4, 32.4, 29.5, 27.8, 24.0, and 20.2 ppm.
values in degrees of about 8.7, 22.2, and 23.5; or (ii) a solid state carbon-13 CPMAS NMR comprising peaks at about 174.7, 172.0, 161.4, 156.8, 156.3, 149.5, 142.1, 133.9, 128.2, 121.3, 105.0, 76.9, 60.7, 57.5, 55.1, 53.5, 35.8, 34.7, 33.4, 32.4, 29.5, 27.8, 24.0, and 20.2 ppm.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161525462P | 2011-08-19 | 2011-08-19 | |
| US61/525,462 | 2011-08-19 | ||
| US201161533439P | 2011-09-12 | 2011-09-12 | |
| US61/533,439 | 2011-09-12 | ||
| US201161533915P | 2011-09-13 | 2011-09-13 | |
| US61/533,915 | 2011-09-13 | ||
| US201161539540P | 2011-09-27 | 2011-09-27 | |
| US61/539,540 | 2011-09-27 | ||
| PCT/US2012/051177 WO2013028470A1 (en) | 2011-08-19 | 2012-08-16 | Process and intermediates for preparing macrolactams |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2844388A1 true CA2844388A1 (en) | 2013-02-28 |
Family
ID=47746773
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2844388A Abandoned CA2844388A1 (en) | 2011-08-19 | 2012-08-16 | Process and intermediates for preparing macrolactams |
| CA2844386A Abandoned CA2844386A1 (en) | 2011-08-19 | 2012-08-16 | Crystal forms of a hcv protease inhibitor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2844386A Abandoned CA2844386A1 (en) | 2011-08-19 | 2012-08-16 | Crystal forms of a hcv protease inhibitor |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9242917B2 (en) |
| EP (3) | EP2744336B1 (en) |
| JP (2) | JP2014524442A (en) |
| KR (2) | KR20140053330A (en) |
| CN (2) | CN103874414A (en) |
| AU (2) | AU2012299218A1 (en) |
| BR (2) | BR112014003798A2 (en) |
| CA (2) | CA2844388A1 (en) |
| MX (2) | MX2014001945A (en) |
| RU (2) | RU2014110400A (en) |
| WO (3) | WO2013028470A1 (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8828930B2 (en) | 2009-07-30 | 2014-09-09 | Merck Sharp & Dohme Corp. | Hepatitis C virus NS3 protease inhibitors |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| BR112014003798A2 (en) * | 2011-08-19 | 2017-03-01 | Merck Sharp & Dohme | method for making a compound, and, compound |
| UA119315C2 (en) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Inhibitors of hepatitis c virus |
| BR112015007879A2 (en) | 2012-10-19 | 2017-07-04 | Bristol Myers Squibb Co | hepatitis c virus inhibitors |
| US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| US9580463B2 (en) | 2013-03-07 | 2017-02-28 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN105073758B (en) | 2013-03-15 | 2017-08-11 | 吉利德科学公司 | Hepatitis c virus inhibitors |
| EP3057926A4 (en) * | 2013-10-18 | 2017-07-12 | Merck Sharp & Dohme Corp. | Methods and intermediates for preparing macrolactams |
| WO2015095437A1 (en) * | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Methods and intermediates for the preparation of macrolactams |
| MY193524A (en) | 2014-01-24 | 2022-10-18 | Turning Point Therapeutics Inc | Diaryl macrocycles as modulators of protein kinases |
| JP2017518319A (en) * | 2014-06-06 | 2017-07-06 | アッヴィ・インコーポレイテッド | Crystal form |
| CA2989327A1 (en) | 2015-07-02 | 2017-01-05 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| MX2017017081A (en) * | 2015-07-06 | 2018-08-16 | Tp Therapeutics Inc | Diaryl macrocycle polymorph. |
| CA2992324A1 (en) | 2015-07-21 | 2017-01-26 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles and uses thereof |
| CN109562113A (en) | 2016-05-10 | 2019-04-02 | C4医药公司 | Loop coil degron body for target protein degradation |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CN109562107A (en) | 2016-05-10 | 2019-04-02 | C4医药公司 | Heterocycle degron body for target protein degradation |
| US10689400B2 (en) | 2016-07-28 | 2020-06-23 | Turning Point Therapeutics, Inc. | Macrocycle kinase inhibitors |
| TWI808958B (en) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | Combination therapy involving diaryl macrocyclic compounds |
| US11286264B2 (en) | 2017-07-28 | 2022-03-29 | Turning Point Therapeutics, Inc. | Macrocyclic compounds and uses thereof |
| DK3728271T3 (en) | 2017-12-19 | 2022-12-19 | Turning Point Therapeutics Inc | Macrocyclic compounds for the treatment of diseases |
| CN111057045A (en) * | 2019-12-18 | 2020-04-24 | 安徽红杉生物医药科技有限公司 | HCV NS3/4A protease inhibitor intermediate, and synthesis method and application thereof |
| CN112174982A (en) * | 2020-09-10 | 2021-01-05 | 上海希迈医药科技有限公司 | Lopitinib crystal form and preparation method thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4871868A (en) | 1987-03-11 | 1989-10-03 | Takeda Chemical Industries, Ltd. | Production of substituted acetylenic compounds |
| GB9207987D0 (en) * | 1992-04-10 | 1992-05-27 | Smithkline Beecham Plc | Novel container and closure |
| US5716960A (en) * | 1995-01-13 | 1998-02-10 | U.S. Bioscience Inc. And Individuals | Crystalline trimetrexate salts and the process for making the same |
| NO317155B1 (en) * | 1997-02-04 | 2004-08-30 | Ono Pharmaceutical Co | <Omega> -cycloalkyl-prostaglandin-E <N> 2 </ N> derivatives |
| ZA98879B (en) * | 1997-02-04 | 1998-08-03 | Ono Pharmaceutical Co | Omega-cycloalkyl-prostaglandin e2 derivatives |
| CN102372705A (en) * | 2005-02-18 | 2012-03-14 | 田边三菱制药株式会社 | Salt of proline derivative, solvate thereof, and production method thereof |
| WO2006102087A2 (en) | 2005-03-22 | 2006-09-28 | Merck & Co., Inc. | Hcv protease substrates |
| JP4705164B2 (en) | 2005-05-02 | 2011-06-22 | メルク・シャープ・エンド・ドーム・コーポレイション | HCV NS3 protease inhibitor |
| TWI387603B (en) | 2005-07-20 | 2013-03-01 | Merck Sharp & Dohme | Hcv ns3 protease inhibitors |
| CN101228181B (en) * | 2005-07-20 | 2013-09-18 | 默沙东公司 | Hcv ns3 protease inhibitors |
| EP1913016B1 (en) | 2005-08-01 | 2013-01-16 | Merck Sharp & Dohme Corp. | Macrocyclic peptides as hcv ns3 protease inhibitors |
| CA2645234A1 (en) | 2006-03-07 | 2007-09-13 | The Procter & Gamble Company | Compositions for oxidatively dyeing keratin fibers and methods for using such compositions |
| GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| CA2667266C (en) | 2006-10-24 | 2015-11-24 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| WO2008051477A2 (en) | 2006-10-24 | 2008-05-02 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| AU2007318165B2 (en) | 2006-10-27 | 2011-11-17 | Msd Italia S.R.L. | HCV NS3 protease inhibitors |
| WO2008057208A2 (en) | 2006-10-27 | 2008-05-15 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| EP2160392A2 (en) | 2007-05-03 | 2010-03-10 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| CA2699891C (en) | 2007-07-19 | 2013-10-22 | Nigel Liverton | Macrocyclic compounds as antiviral agents |
| AU2009217551B2 (en) | 2008-02-25 | 2014-07-31 | Msd Italia S.R.L. | Therapeutic compounds |
| WO2009131196A1 (en) * | 2008-04-24 | 2009-10-29 | 武田薬品工業株式会社 | Substituted pyrrolidine derivative and use thereof |
| EP2274288A2 (en) | 2008-04-24 | 2011-01-19 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
| WO2009134624A1 (en) | 2008-04-28 | 2009-11-05 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| PT2540350E (en) * | 2008-07-22 | 2014-08-27 | Merck Sharp & Dohme | Combinations of a macrocyclic quinoxaline compound which is an hcv ns3 protease inhibitor with other hcv agents |
| US8828930B2 (en) | 2009-07-30 | 2014-09-09 | Merck Sharp & Dohme Corp. | Hepatitis C virus NS3 protease inhibitors |
| JP5789260B2 (en) * | 2009-08-27 | 2015-10-07 | メルク・シャープ・エンド・ドーム・コーポレイション | Method for preparing protease inhibitor of hepatitis C virus |
| BR112014003798A2 (en) | 2011-08-19 | 2017-03-01 | Merck Sharp & Dohme | method for making a compound, and, compound |
-
2012
- 2012-08-16 BR BR112014003798A patent/BR112014003798A2/en not_active IP Right Cessation
- 2012-08-16 JP JP2014526215A patent/JP2014524442A/en active Pending
- 2012-08-16 US US14/239,389 patent/US9242917B2/en active Active
- 2012-08-16 MX MX2014001945A patent/MX2014001945A/en unknown
- 2012-08-16 EP EP12826404.1A patent/EP2744336B1/en not_active Not-in-force
- 2012-08-16 WO PCT/US2012/051177 patent/WO2013028470A1/en active Application Filing
- 2012-08-16 MX MX2014001944A patent/MX2014001944A/en unknown
- 2012-08-16 CN CN201280050361.6A patent/CN103874414A/en active Pending
- 2012-08-16 EP EP12825726.8A patent/EP2744331A4/en not_active Withdrawn
- 2012-08-16 CA CA2844388A patent/CA2844388A1/en not_active Abandoned
- 2012-08-16 US US14/239,393 patent/US9238604B2/en active Active
- 2012-08-16 RU RU2014110400/04A patent/RU2014110400A/en not_active Application Discontinuation
- 2012-08-16 RU RU2014110399/04A patent/RU2014110399A/en not_active Application Discontinuation
- 2012-08-16 AU AU2012299218A patent/AU2012299218A1/en not_active Abandoned
- 2012-08-16 CA CA2844386A patent/CA2844386A1/en not_active Abandoned
- 2012-08-16 WO PCT/US2012/051168 patent/WO2013028465A1/en active Application Filing
- 2012-08-16 KR KR1020147006858A patent/KR20140053330A/en not_active Application Discontinuation
- 2012-08-16 CN CN201280050382.8A patent/CN103889439A/en active Pending
- 2012-08-16 EP EP12825540.3A patent/EP2744507A4/en not_active Withdrawn
- 2012-08-16 JP JP2014526217A patent/JP2014521750A/en active Pending
- 2012-08-16 AU AU2012299223A patent/AU2012299223A1/en not_active Abandoned
- 2012-08-16 KR KR1020147006888A patent/KR20140059236A/en not_active Application Discontinuation
- 2012-08-16 US US14/239,391 patent/US9073825B2/en active Active
- 2012-08-16 WO PCT/US2012/051182 patent/WO2013028471A1/en active Application Filing
- 2012-08-16 BR BR112014003802A patent/BR112014003802A2/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013028471A1 (en) | 2013-02-28 |
| EP2744336B1 (en) | 2017-07-05 |
| EP2744336A1 (en) | 2014-06-25 |
| US20140243519A1 (en) | 2014-08-28 |
| CA2844386A1 (en) | 2013-02-28 |
| CN103874414A (en) | 2014-06-18 |
| WO2013028465A1 (en) | 2013-02-28 |
| KR20140053330A (en) | 2014-05-07 |
| US9073825B2 (en) | 2015-07-07 |
| US20140200343A1 (en) | 2014-07-17 |
| EP2744507A4 (en) | 2015-01-28 |
| RU2014110400A (en) | 2015-09-27 |
| BR112014003798A2 (en) | 2017-03-01 |
| US9242917B2 (en) | 2016-01-26 |
| US9238604B2 (en) | 2016-01-19 |
| CN103889439A (en) | 2014-06-25 |
| US20140206605A1 (en) | 2014-07-24 |
| AU2012299223A1 (en) | 2014-02-27 |
| MX2014001945A (en) | 2014-03-27 |
| EP2744507A1 (en) | 2014-06-25 |
| MX2014001944A (en) | 2014-03-27 |
| JP2014524442A (en) | 2014-09-22 |
| EP2744331A1 (en) | 2014-06-25 |
| JP2014521750A (en) | 2014-08-28 |
| BR112014003802A2 (en) | 2017-06-13 |
| RU2014110399A (en) | 2015-09-27 |
| KR20140059236A (en) | 2014-05-15 |
| WO2013028470A1 (en) | 2013-02-28 |
| AU2012299218A1 (en) | 2014-02-20 |
| EP2744336A4 (en) | 2014-12-31 |
| EP2744331A4 (en) | 2015-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2844388A1 (en) | Process and intermediates for preparing macrolactams | |
| JP6034802B2 (en) | Methods and intermediates for the preparation of macrocyclic lactams | |
| ES2470568T3 (en) | Hepatitis C virus macrocyclic inhibitors | |
| JP4705164B2 (en) | HCV NS3 protease inhibitor | |
| CN114057702B (en) | Novel inhibitor of coronavirus main protease and preparation method and application thereof | |
| KR20120139706A (en) | Polyheterocyclic compounds highly potent as hcv inhibitors | |
| AU2010286681A1 (en) | Processes for preparing protease inhibitors of hepatitis C virus | |
| CN103387601B (en) | Anti-dengue virus (DENV) heterocyclic peptide compounds and preparing methods and uses thereof | |
| CN106883279A (en) | A kind of prodrug, its preparation method, medical composition and its use | |
| CN103476260A (en) | Processes for preparing inhibitors of the hepatitis C virus | |
| WO2015095430A1 (en) | Methods and intermediates for the preparation of macrolactams | |
| CN109134511B (en) | Largazole analogue with C19 fluorinated, preparation method and application thereof | |
| CN106967141B (en) | Nucleoside phosphoramidate compounds and pharmaceutical compositions and uses thereof | |
| CN108191957A (en) | Tripeptides macrocyclic derivatives and its preparation method and application | |
| CN103421083A (en) | Anti-dengue virus heterocycle peptide compounds having 1,2,3-triazole structure, preparation method and use thereof | |
| WO2015095437A1 (en) | Methods and intermediates for the preparation of macrolactams | |
| CN117659038A (en) | Water-soluble triptolide prodrug compound and synthetic method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20180816 |